Document:

EX-10.1

LOAN AND SECURITY AGREEMENT

THIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of May 27, 2011 (the “Closing
Date”) by and among MIDCAP FUNDING III, LLC, a Delaware limited liability company, with an office
located at 7735 Old Georgetown Road, Suite 400, Bethesda, Maryland 20814 (“MidCap”), as collateral
agent (“Agent”), the Lenders listed on Schedule 1 hereto and otherwise party hereto from time to
time (each a “Lender”, and collectively the “Lenders”), and EPICEPT CORPORATION, a Delaware
corporation (“EpiCept”), MAXIM PHARMACEUTICALS INC., a Delaware corporation, and CYTOVIA, INC., a
Delaware corporation (either individually or collectively as the context may require, the
“Borrower”), provides the terms on which Lenders agree to lend to Borrower and Borrower shall repay
Lenders. The parties agree as follows:

1. ACCOUNTING AND OTHER TERMS

Accounting terms not defined in this Agreement shall be construed in accordance with GAAP.
Calculations and determinations must be made in accordance with GAAP. Capitalized terms not
otherwise defined in this Agreement shall have the meanings set forth in Section 14. All other
terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by
the Code to the extent such terms are defined therein.

2. LOAN AND TERMS OF PAYMENT

2.1 Promise to Pay. Borrower hereby unconditionally promises to pay to Agent, for
payment to each Lender in accordance with its respective Pro Rata Share, the outstanding principal
amount of all Credit Extensions made by the Lenders, and accrued and unpaid interest thereon, and
any other amounts due hereunder as and when due in accordance with this Agreement.

2.2 Term Loans.

(a) Availability. Subject to the terms and conditions of this Agreement, during the
Draw Period, the Lenders agree, severally and not jointly, to make one or more term loans to
Borrower in an aggregate amount up to TEN MILLION, SIX HUNDRED THOUSAND AND NO/100 Dollars
($10,600,000.00) according to each Lender’s Term Loan Commitment as set forth on Schedule 1 hereto
(such term loans are hereinafter referred to individually as a “Term Loan”, and collectively as the
“Term Loans”). After repayment, no Term Loan may be re-borrowed. The Term Loans shall be
available in two tranches. The first tranche (“Tranche One”) shall be in an amount equal to EIGHT
MILLION, SIX HUNDRED THOUSAND AND NO/100 Dollars ($8,600,000.00) and shall be advanced on the
Closing Date. The second tranche (“Tranche Two”) shall be in an amount equal to but not less than
TWO MILLION AND NO/100 Dollars ($2,000,000.00) and shall be available to be advanced in a single
advance during the Draw Period, but only after the Tranche Two Eligibility Date.

(b) Interest Payments and Repayment. Commencing on the first (1st) Payment
Date following the Funding Date of Tranche One, and continuing on the Payment Date of each
successive month thereafter through and including the Maturity Date, Borrower shall make monthly
payments of interest to each Lender in accordance with its respective Pro Rata Share, in arrears,
and calculated as set forth in Section 2.3. Commencing on the Amortization Date, and continuing on
the Payment Date of each successive month thereafter through and including the Maturity Date,
Borrower shall make consecutive monthly payments of principal to each Lender in accordance with its
respective Pro Rata Share, as calculated by Agent based upon: (i) the amount of such Lender’s Term
Loans, (ii) the effective rate of interest, as determined in Section 2.3, and (iii) a straight-line
amortization schedule ending on the Maturity Date. All unpaid principal and accrued interest with
respect to the Term Loans is due and payable in full on the Maturity Date. The Term Loans may be
prepaid only in accordance with Sections 2.2(c) and 2.2(d).

(c) Mandatory Prepayments. If the Term Loans are accelerated following the
occurrence of an Event of Default, Borrower shall immediately pay to Agent, for payment to each
Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all
outstanding principal of the Term Loans and all other Obligations, and all accrued and unpaid
interest thereon, plus (ii) the Final Payment, plus (iii) the Prepayment Fee, plus (iv) all other
sums that shall have become due and payable, including Lenders’ Expenses.

(d) Permitted Prepayment of Loans. Borrower shall have the option to prepay all, but
not less than all, of the Term Loans advanced by the Lenders under this Agreement; provided,
however, that Borrower (i) provides written notice to Agent of its election to prepay the Term
Loans at least thirty (30) days prior to such prepayment, and (ii) pays to Agent, for payment to
each Lender in accordance with its respective Pro Rata Share, on the date of such prepayment, an
amount equal to the sum of: (A) all outstanding principal of the Term Loans and all other
Obligations, and all accrued interest thereon, plus (B) the Final Payment, plus (C) the Prepayment
Fee, plus (D) all other sums that shall have become due and payable, including Lenders’ Expenses.

2.3 Payment of Interest on the Credit Extensions.

(a) Computation of Interest. Interest on the Credit Extensions and all fees payable
hereunder shall be computed on the basis of a 360-day year and the actual number of days elapsed in
the period during which such interest accrues. In computing interest on any Credit Extension, the
date of the making of such Credit Extension shall be included and the date of payment shall be
excluded; provided, however, that if any Credit Extension is repaid on the same day on which it is
made, such day shall be included in computing interest on such Credit Extension.

(b) Interest Rate Determination. Subject to the provisions of Section 2.3(c) below,
each Term Loan shall bear interest on the outstanding principal amount thereof from the date when
made until paid in full at a rate per annum equal to the sum of (i) the greater of (A) the LIBOR
Rate in effect for the applicable Interest Period and (B) three and one half of one percent (3.5%),
plus (ii) the LIBOR Rate Margin adjusted on the first (1st) day of each Interest Period
and fixed for the duration of each such Interest Period. As of each Interest Rate Determination
Date, Agent shall determine (which determination shall, absent manifest error in calculation, be
final, conclusive and binding upon all parties) the interest rate that shall apply to the Term Loan
for which an interest rate is then being determined for the applicable Interest Period. In the
event that Agent shall have determined (which determination shall be final and conclusive and
binding upon all parties hereto), as of any Interest Rate Determination Date with respect to any
Term Loan, that adequate and fair means do not exist for ascertaining the interest rate applicable
to such Term Loan on the basis provided for in the definition of Base LIBOR Rate, then Agent may
select a comparable replacement index and corresponding margin.

(c) Default Rate. Immediately upon the occurrence and during the continuance of an
Event of Default, Obligations shall bear interest at a rate per annum that is five percent (5.0%)
above the rate that is otherwise applicable thereto (the “Default Rate”). Payment or acceptance of
the increased interest rate provided in this Section 2.3(c) is not a permitted alternative to
timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or
limit any rights or remedies of Agent or Lenders.

(d) Debit of Accounts. Any Lender may debit any of Borrower’s Deposit Accounts,
including the Designated Deposit Account, for principal and interest payments when due or any other
amounts Borrower owes the Lenders under the Loan Documents when due. These debits shall not
constitute a set-off.

(e) Payments. Payments of principal and/or interest received after 3:00 PM Eastern
Time are considered received at the opening of business on the next Business Day. When a payment
is due on a day that is not a Business Day, the payment is due the next Business Day and additional
fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by
Borrower hereunder or under any other Loan Document, including payments of principal and interest
made hereunder and pursuant to any other Loan Document, and all fees, expenses, indemnities and
reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the
United States and in immediately available funds. All payments required under this Agreement are
to be made directly to Agent unless otherwise directed by Agent in writing.

(f) Maximum Lawful Rate. In no event shall the interest charged hereunder, with
respect to the notes (if any) or any other obligations of Borrower under any of the Loan Documents
exceed the maximum amount permitted under the Laws of the State of Maryland. Notwithstanding
anything to the contrary herein or elsewhere, if at any time the rate of interest payable hereunder
or under any note or other Loan Document (the “Stated Rate”) would exceed the highest rate of
interest permitted under any applicable Law to be charged (the “Maximum Lawful Rate”), then for so
long as the Maximum Lawful Rate would be so exceeded, the rate of interest payable shall be equal
to the Maximum Lawful Rate; provided, however, that if at any time thereafter the Stated Rate is
less than the Maximum Lawful Rate, Borrower shall, to the extent permitted by Law, continue to pay
interest at the Maximum Lawful Rate until such time as the total interest received is equal to the
total interest which would have been received had the Stated Rate been (but for the operation of
this provision) the interest rate payable. Thereafter, the interest rate payable shall be the
Stated Rate unless and until the Stated Rate again would exceed the Maximum Lawful Rate, in which
event this provision shall again apply. In no event shall the total interest received by any
Lender exceed the amount which it could lawfully have received, had the interest been calculated
for the full term hereof at the Maximum Lawful Rate. If, notwithstanding the prior sentence, any
Lender has received interest hereunder in excess of the Maximum Lawful Rate, then such excess
amount shall be applied to the reduction of the principal balance of such Lender’s Term Loan or to
other amounts (other than interest) payable hereunder, and if no such principal or other amounts
are then outstanding, such excess or part thereof remaining shall be paid to Borrower. In
computing interest payable with reference to the Maximum Lawful Rate applicable to any Lender, such
interest shall be calculated at a daily rate equal to the Maximum Lawful Rate divided by the number
of days in the year in which such calculation is made.

2.4 Fees and Expenses. Borrower shall pay to Agent, for payment to each Lender:

(a) Origination Fee. A non-refundable origination fee to each Lender, in accordance
with its respective Pro Rata Share, equal to the product of (i) one half of one percent (0.50%)
multiplied by (ii) the aggregate Term Loan Commitment on the Closing Date, of which the pro rata
portion of the origination fee allocable to Tranche One shall be due and payable on the Closing
Date, and the pro rata portion of the origination fee allocable to Tranche Two shall be due and
payable on the Funding Date of Tranche Two;

(b) Final Payment. The Final Payment, when due under Section 2.2(c) or 2.2(d), or
otherwise on the Maturity Date, to each Lender, in accordance with its respective Pro Rata Share;

(c) Prepayment Fee. The Prepayment Fee, when due under Section 2.2(c) or 2.2(d), to
each Lender, in accordance with its respective Pro Rata Share immediately prior to application of
the corresponding prepayment; and

(d) Lenders’ Expenses. All of Lenders’ Expenses (including reasonable attorneys’ fees
and expenses for documentation and negotiation of this Agreement) incurred through and after the
Closing Date, when due (and in the absence of any other due date specified herein, such Lenders’
Expenses shall be due upon demand).

2.5 Additional Costs. If any new Law or regulation increases a Lender’s costs or
reduces its income for any Term Loan, Borrower shall pay the increase in cost or reduction in
income or additional expense; provided, however, that Borrower shall not be liable for any amount
attributable to any period before one hundred eighty (180) days prior to the date such Lender
notifies Borrower of such increased costs. Each Lender agrees that it shall allocate any increased
costs among its customers similarly affected in good faith and in a manner consistent with such
Lender’s customary practice.

2.6 Payments and Taxes. Any and all payments made by Borrower under this Agreement or
any other Loan Document shall be made free and clear of and without deduction for any and all
present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or
other charges imposed by any governmental authority (including any interest, additions to tax or
penalties applicable thereto) other than any taxes imposed on or measured by any Lender’s overall
net income and franchise taxes imposed on it (in lieu of net income taxes), by a jurisdiction (or
any political subdivision thereof) as a result of any Lender being organized or resident,
conducting business (other than a business deemed to arise from such Lender having executed,
delivered or performed its obligations or received a payment under, or enforced, or otherwise with
respect to, this Agreement or any other Loan Document) or having its principal office in such
jurisdiction (“Indemnified Taxes”). If any Indemnified Taxes shall be required by Law to be
withheld or deducted from or in respect of any sum payable under this Agreement or any other Loan
Document to any Lender, (a) an additional amount shall be payable as may be necessary so that,
after making all required withholdings or deductions (including withholdings or deductions
applicable to additional sums payable under this Section) such Lender receives an amount equal to
the sum it would have received had no such withholdings or deductions been made, (b) Borrower shall
make such withholdings or deductions, (c) Borrower shall pay the full amount withheld or deducted
to the relevant taxing authority or other authority in accordance with applicable Law, and (d)
Borrower shall deliver to such Lender evidence of such payment. Borrower’s obligation hereunder
shall survive the termination of this Agreement.

2.7 Secured Promissory Notes. Each Term Loan shall be evidenced by a Secured
Promissory Note in the form attached as Exhibit D hereto (each a “Secured Promissory Note”), and
shall be repayable as set forth herein. Borrower irrevocably authorizes each Lender to make or
cause to be made, on or about the Funding Date of any Term Loan or at the time of receipt of any
payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such
Lender’s Secured Promissory Note Record reflecting the making of such Term Loan or (as the case may
be) the receipt of such payment. The outstanding amount of each Term Loan set forth on such
Lender’s Secured Promissory Note Record shall be prima facie evidence of the principal amount
thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording,
any such amount on such Lender’s Secured Promissory Note Record shall not limit or otherwise affect
the obligations of Borrower hereunder or under any Secured Promissory Note to make payments of
principal of or interest on any Secured Promissory Note when due. Upon receipt of an affidavit of
an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory
Note, Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same
principal amount thereof and of like tenor.

2.8 Issuance of Warrants to Lenders. Borrower has duly authorized issuance of the
Warrants substantially in the form attached hereto as Exhibit E.

3. CONDITIONS OF LOANS

3.1 Conditions Precedent to Initial Credit Extension. Each Lender’s obligation to
make a Term Loan is subject to the condition precedent that Agent shall consent to or shall have
received, in form and substance satisfactory to Agent, such documents, and completion of such other
matters, as Agent may reasonably deem necessary or appropriate, including, without limitation:

(a) duly executed original signatures to this Agreement, the Perfection Certificate and the
other Loan Documents to which Borrower is a party;

(b) duly executed original Secured Promissory Notes in favor of each Lender with a face amount
equal to such Lender’s Term Loan Commitment;

(c) a pledge agreement, in form and substance reasonably satisfactory to Agent, executed by
each Loan Party and pledging to Agent, for the benefit of itself and the Lenders, a security
interest in (a) 100% of the shares of the outstanding capital stock, of any class, of each
Subsidiary (as defined below) of each Loan Party that is incorporated under the laws of any State
of the United States or the District of Columbia (other than the Meda Royalty Subsidiary), (b)
shares of the outstanding capital stock of any class of each Foreign Subsidiary that constitute 65%
of the total combined voting power of all capital stock of all classes of such Foreign Subsidiary
(provided, that with respect to any Foreign Subsidiary, to the extent that there is no
material increase in Borrower’s federal income tax liability from a pledge or one hundred percent
(100%) of such shares of such Foreign Subsidiary, such pledge shall be for one-hundred percent
(100%) of such Foreign Subsidiary’s outstanding voting and non-voting capital stock and stock
equivalents) and (c) any and all Indebtedness (as defined below) owing to Loan Parties (the
“Pledge Agreement”);

(d) the Operating Documents of Borrower certified by the Secretary of State of the state of
organization of Borrower as of a date no earlier than thirty (30) days prior to the Closing Date;

(e) good standing certificates dated as of a date no earlier than thirty (30) days prior to
the Closing Date to the effect that Borrower is qualified to transact business in all states in
which the nature of Borrower’s business so requires;

(f) duly executed original signatures to the completed Borrowing Resolutions for Borrower;

(g) certified copies, dated as of a recent date, of financing statement searches, as Agent
shall request, accompanied by written evidence (including any UCC termination statements) that the
Liens indicated in any such financing statements either constitute Permitted Liens or have been or,
in connection with the initial Credit Extension, will be terminated or released;

(h) a duly executed legal opinion of Borrower’s counsel dated as of the Closing Date;

(i) evidence satisfactory to Agent that the insurance policies required by Section 6.5 hereof
are in full force and effect, together with appropriate evidence showing loss payable and/or
additional insured clauses or endorsements in favor of Agent, for the ratable benefit of Lenders;

(j) payment of the Origination Fee described in Section 2.4(a) and the Lenders’ Expenses
described in Section 2.4(d); and

(k) duly executed original signature pages to the Warrants.

3.2 Conditions Precedent to all Credit Extensions. The obligation of each Lender to
make each Credit Extension, including the initial Credit Extension, is subject to the following
conditions precedent:

(a) timely receipt by the Agent of an executed Payment/Advance Form in the form of Exhibit B
attached hereto;

(b) the representations and warranties in Section 5 shall be true, correct and complete in all
material respects on the date of the Payment/Advance Form and on the Funding Date of each Credit
Extension; provided, however, that such materiality qualifier shall not be applicable to any
representations and warranties that already are qualified or modified by materiality in the text
thereof; and provided, further that those representations and warranties expressly referring to a
specific date shall be true, accurate and complete in all material respects as of such date, and no
Default or Event of Default shall have occurred and be continuing or result from the Credit
Extension. Each Credit Extension is Borrower’s representation and warranty on that date that the
representations and warranties in Section 5 remain true, accurate and complete in all material
respects; provided, however, that such materiality qualifier shall not be applicable to any
representations and warranties that already are qualified or modified by materiality in the text
thereof; and provided, further that those representations and warranties expressly referring to a
specific date shall be true, accurate and complete in all material respects as of such date; and

(c) in such Lender’s reasonable discretion, there has not been any Material Adverse Change or
any material impairment in the general affairs, management, results of operation, financial
condition or the prospect of repayment of the Obligations.

3.3 Covenant to Deliver. Borrower agrees to deliver to Agent each item required to be
delivered to Agent under this Agreement as a condition precedent to any Credit Extension. Borrower
expressly agrees that a Credit Extension made prior to the receipt by Agent of any such item shall
not constitute a waiver by the Lenders of Borrower’s obligation to deliver such item, and any such
Credit Extension in the absence of a required item shall be made in Agent’s sole discretion.

3.4 Procedures for Borrowing. Subject to the prior satisfaction of all other
applicable conditions to the making of a Term Loan set forth in this Agreement, to obtain a Term
Loan, Borrower shall notify Agent (which notice shall be irrevocable) by electronic mail,
facsimile, or telephone by 12:00 noon Eastern time ten (10) Business Days prior to the date the
Term Loan is to be made. Together with any such electronic or facsimile notification, Borrower
shall deliver to Agent by electronic mail or facsimile a completed Payment/Advance Form executed by
a Responsible Officer or his or her designee. Upon receipt of a Payment/Advance Form, Agent shall
promptly provide a copy of the same to each Lender. Agent may rely on any telephone notice given
by a person whom Agent reasonably believes is a Responsible Officer or designee.

4. CREATION OF SECURITY INTEREST

4.1 Grant of Security Interest. Borrower hereby grants Agent, for the ratable benefit
of the Lenders, to secure the payment and performance in full of all of the Obligations, a
continuing security interest in, and pledges to Agent, for the ratable benefit of the Lenders, the
Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds
and products thereof. Borrower represents, warrants, and covenants that the security interest
granted herein is and shall at all times continue to be a first priority perfected security
interest in the Collateral, subject only to Permitted Liens that may have priority by operation of
applicable Law. If Borrower shall acquire a commercial tort claim (as defined in the Code),
Borrower shall promptly notify Agent in a writing signed by Borrower of the general details thereof
(and further details as may be required by Agent) and grant to Agent, for the ratable benefit of
the Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the
terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to
Agent.

4.2 Authorization to File Financing Statements. Borrower hereby authorizes Agent to
file financing statements, without notice to Borrower, with all appropriate jurisdictions to
perfect or protect Agent’s and each Lender’s interest or rights hereunder, including a notice that
any disposition of the Collateral, by either Borrower or any other Person, shall be deemed to
violate the rights of Agent and the Lenders under the Code. Such financing statements may indicate
the Collateral as “all assets of Debtor” or words of similar effect, or as being of an equal or
lesser scope, or with greater detail, all in Agent’s sole discretion.

5. REPRESENTATIONS AND WARRANTIES

	 	 	 	 	 
	Borrower represents and warrants as follows at all times unless expressly provided below:
	 	5.1	 	 	Due Organization, Authorization: Power and Authority.

	 	 	 	 	 

(a) Borrower and each of its Subsidiaries (if any) are duly existing and in good standing, as
Registered Organizations in their respective jurisdictions of formation and are qualified and
licensed to do business and are in good standing in any jurisdiction in which the conduct of their
business or their ownership of property requires that they be qualified except where the failure to
do so could not reasonably be expected to have a Material Adverse Change. Borrower represents and
warrants that (i) Borrower’s exact legal name is that indicated on Schedule 5.1 and on the
signature page hereof; (ii) Borrower is an organization of the type and is organized in the
jurisdiction set forth on Schedule 5.1; (iii) Schedule 5.1 accurately sets forth Borrower’s
organizational identification number or accurately states that Borrower has none; (iv) Schedule 5.1
accurately sets forth Borrower’s place of business, or, if more than one, its chief executive
office as well as Borrower’s mailing address (if different than its chief executive office); and
(v) Borrower (and each of its predecessors) has not, in the past five (5) years, changed its
jurisdiction of formation, organizational structure or type, or any organizational number assigned
by its jurisdiction. Further, in connection with this Agreement, Borrower has delivered to Agent a
completed Perfection Certificate signed by Borrower (the “Perfection Certificate”). All other
information set forth on the Perfection Certificate pertaining to Borrower and each of its
Subsidiaries is accurate and complete (it being understood and agreed that Borrower may from time
to time update certain information in the Perfection Certificate after the Closing Date, to the
extent permitted by one or more specific provisions in this Agreement). If Borrower is not now a
Registered Organization but later becomes one, Borrower shall promptly notify Agent of such
occurrence and provide Agent with Borrower’s organizational identification number.

(b) The execution, delivery and performance by Borrower of the Loan Documents to which it is a
party have been duly authorized, and do not (i) conflict with any of Borrower’s organizational
documents; (ii) contravene, conflict with, constitute a default under or violate any material
Requirement of Law; (iii) contravene, conflict or violate any applicable order, writ, judgment,
injunction, decree, determination or award of any Governmental Authority by which Borrower or any
of its Subsidiaries or any of their property or assets may be bound or affected; (iv) require any
action by, filing, registration, or qualification with, or Governmental Approval from, any
Governmental Authority (except such Governmental Approvals which have already been obtained and are
in full force and effect); or (v) constitute an event of default under any material agreement by
which Borrower or any of its Subsidiaries or their respective properties is bound. Borrower is not
in default under any agreement to which it is a party or by which it is bound in which the default
could reasonably be expected to have a Material Adverse Change.

5.2 Collateral.

(a) Collateral Accounts. Borrower has good title to, has rights in, and has the power
to transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and
clear of any and all Liens, except Permitted Liens. Borrower has no Deposit Accounts, Securities
Accounts, Commodity Accounts or other investment accounts other than the Collateral Accounts with
the banks and/or financial institutions listed on Schedule 5.2(a), for which Borrower has given
Agent notice and taken such actions as are necessary to grant to Agent, for the ratable benefit of
Lenders, a perfected security interest therein.

(b) Accounts. The Accounts are bona fide, existing obligations of the Account
Debtors.

(c) Inventory. All Inventory is in all material respects of good and marketable
quality, free from material defects, other than any inventory of drug product that is past its
expiration date and is or will be written off from time to time in accordance with GAAP and
applicable laws.

(d) Intellectual Property and License Agreements. A list of all of Borrower’s
Intellectual Property and all license agreements, sublicenses, or other rights of any Loan Party to
use Intellectual Property (including all in-bound license agreements, but excluding
over-the-counter software that is commercially available to the public) is set forth on Schedule
5.2(d), which indicates, for each item of property: (i) the Borrower’s name owning such
Intellectual Property or licensee to such license agreement; (ii) Borrower’s identifier for such
property (i.e., name of patent, license, etc.), (iii) whether such property is Intellectual
Property (or application therefor) owned by Borrower or is property to which Borrower has rights
pursuant to a license agreement, (iv) the expiration date of such Intellectual Property or license
agreement, and (v) whether such property constitutes Material Intellectual Property. In the case
of any Material Intellectual Property that is a license agreement, Schedule 5.2(d) further
indicates, for each: (A) the name and address of the licensor, (B) the name and date of the
agreement pursuant to which such item of Material Intellectual Property is licensed, (C) whether or
not such license agreement grants an exclusive license to Borrower, (D) whether there are any
purported restrictions in such license agreement as to the ability of Borrower to grant a security
interest in and/or to transfer any of its rights as a licensee under such license agreement, and
(E) whether a default under or termination of such license agreement could interfere with Agent’s
right to sell or assign such license or any other Collateral. Except as noted on Schedule 5.2(d),
Borrower is the sole owner of its Intellectual Property, except for non-exclusive licenses granted
to its customers in the Ordinary Course of Business as identified on Schedule 5.2(d). Each Patent
is valid and enforceable and no part of the Intellectual Property has been judged invalid or
unenforceable, in whole or in part, and to the best of Borrower’s knowledge, no claim has been made
that any part of the Intellectual Property violates the rights of any third party, except to the
extent such claim could not reasonably be expected to have a Material Adverse Change.

(e) Location of Collateral. On the Closing Date, the Collateral is located at the
address(es) identified on Schedule 5.2(e), and are not in the possession of any third party bailee
(such as a warehouse) except as disclosed Schedule 5.2(e), and as of the Closing Date, no such
third party bailee possesses components of the Collateral in excess of Twenty-Five Thousand Dollars
($25,000) or which constitutes Borrower’s Books. None of the components of the Collateral shall be
maintained at locations other than as disclosed Schedule 5.2(e) on the Closing Date or as permitted
pursuant to Section 7.2. In the event that Borrower, after the Closing Date, intends to store or
otherwise deliver any portion of the Collateral to a bailee in excess of Twenty-Five Thousand
Dollars ($25,000) or which constitutes Borrower’s Books, then Borrower will first receive the
written consent of Agent and such bailee must execute and deliver a bailee agreement in form and
substance satisfactory to Agent in its sole discretion.

5.3 Litigation. Except as disclosed on Schedule 5.3 hereto, there are no actions or
proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or
against Borrower or any of its Subsidiaries involving more than Fifty Thousand Dollars
($50,000.00).

5.4 No Material Deterioration in Financial Condition; Financial Statements. All
consolidated financial statements for Borrower and any of its Subsidiaries delivered to Agent
fairly present, in conformity with GAAP, in all material respects Borrower’s consolidated financial
condition and Borrower’s consolidated results of operations. There has not been any material
deterioration in Borrower’s consolidated financial condition since the date of the most recent
financial statements and projections submitted to Agent.

5.5 Solvency. As of the Closing Date and as of the Funding Date for each Credit
Extension, the fair salable value of Borrower’s assets (including goodwill minus disposition costs)
exceeds the fair value of its liabilities. As of the Closing Date and as of the Funding Date for
each Credit Extension, and after giving effect to the transactions described in this Agreement, (a)
Borrower is not left with unreasonably small capital in relation to its business as presently
conducted, and (b) Borrower is able to pay its debts (including trade debts) as they mature.

5.6 Regulatory Compliance.

(a) Borrower is not an “investment company” or a company “controlled” by an “investment
company” under the Investment Company Act of 1940, as amended. Borrower is not engaged as one of
its important activities in extending credit for margin stock (under Regulations X, T and U of the
Federal Reserve Board of Governors). Borrower has complied in all material respects with the
Federal Fair Labor Standards Act. Neither Borrower nor any of its Subsidiaries is a “holding
company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company”,
as each term is defined and used in the Public Utility Holding Company Act of 2005. Borrower has
not violated any Laws, ordinances or rules, the violation of which could reasonably be expected to
have a Material Adverse Change. None of Borrower’s or any of its Subsidiaries’ properties or
assets has been used by Borrower or any Subsidiary or, to Borrower’s knowledge, by previous
Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other
than in material compliance with applicable Laws. Borrower has obtained all Required Permits, or
has contracted with third parties holding Required Permits, necessary for compliance with all Laws
and all such Required Permits are current. Borrower and each of its Subsidiaries have obtained all
consents, approvals and authorizations of, made all declarations or filings with, and given all
notices to, all Governmental Authorities that are necessary to continue their respective businesses
as currently conducted.

(b) None of the Borrower, its Affiliates or any of their respective agents acting or
benefiting in any capacity in connection with the transactions contemplated by this Agreement is
(i) in violation of any Anti-Terrorism Law, (ii) engages in or conspires to engage in any
transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to
violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person.
Neither Borrower nor, to the knowledge of Borrower, any of its Affiliates or agents acting or
benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x)
conducts any business or engages in making or receiving any contribution of funds, goods or
services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any
transaction relating to, any property or interest in property blocked pursuant to Executive Order
No. 13224, any similar executive order or other Anti-Terrorism Law.

5.7 Subsidiaries; Investments. Borrower does not own any stock, partnership interest
or other equity securities, except for Permitted Investments.

5.8 Tax Returns and Payments; Pension Contributions. Borrower has timely filed all
required tax returns and reports, and Borrower and its Subsidiaries have timely paid all foreign,
federal, state and local taxes, assessments, deposits and contributions owed by Borrower. Borrower
may defer payment of any contested taxes, provided, however, that Borrower (a) in good faith
contests its obligation to pay the taxes by appropriate proceedings promptly and diligently
instituted and conducted, (b) notifies Agent in writing of the commencement of, and any material
development in, the proceedings, and (c) posts bonds or takes any other steps required to prevent
the governmental authority levying such contested taxes from obtaining a Lien upon any of the
Collateral that is other than a “Permitted Lien”. Borrower is unaware of any claims or adjustments
proposed for any of Borrower’s prior tax years which could result in additional taxes becoming due
and payable by Borrower. Borrower has paid all amounts necessary to fund all present pension,
profit sharing and deferred compensation plans in accordance with their terms, and Borrower has not
withdrawn from participation in, and has not permitted partial or complete termination of, or
permitted the occurrence of any other event with respect to, any such plan which could reasonably
be expected to result in any liability of Borrower, including any liability to the Pension Benefit
Guaranty Corporation or its successors or any other governmental agency.

5.9 Use of Proceeds. Borrower shall use the proceeds of the Credit Extensions solely
as working capital and to fund its general business requirements, and not for personal, family,
household or agricultural purposes.

5.10 Full Disclosure. No written representation, warranty or other statement of
Borrower in any certificate or written statement given to Agent or any Lender, as of the date such
representation, warranty, or other statement was made, taken together with all such written
certificates and written statements given to Agent or any Lender, contains any untrue statement of
a material fact or omits to state a material fact necessary to make the statements contained in the
certificates or statements not misleading (it being recognized that the projections and forecasts
provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts
and that actual results during the period or periods covered by such projections and forecasts may
differ from the projected or forecasted results).

5.11 Regulatory Developments.

(a) All Products and all Required Permits are listed on Schedule 5.11 (as updated from time to
time pursuant to Section 6.2(e)), and Borrower has delivered to Agent a copy of all Required
Permits to the extent requested by Agent pursuant to Section 6.2(e).

(b) Without limiting the generality of Section 5.6 above, with respect to any Product being
tested or manufactured by Borrower, Borrower has received, and such Product is the subject of, all
Required Permits needed in connection with the testing or manufacture of such Product as such
testing is currently being conducted by or on behalf of Borrower, and Borrower has not received any
notice from any applicable Governmental Authority, specifically including the FDA, that such
Governmental Authority is conducting an investigation or review of (i) Borrower’s manufacturing
facilities and processes for such Product which have disclosed any material deficiencies or
violations of Laws and/or the Required Permits related to the manufacture of such Product, or (ii)
any such Required Permit or that any such Required Permit has been revoked or withdrawn, nor has
any such Governmental Authority issued any order or recommendation stating that the development,
testing and/or manufacturing of such Product by Borrower should cease.

(c) Without limiting the generality of Section 5.6 above, with respect to any Product marketed
or sold by Borrower, Borrower has received, and such Product is the subject of, all Required
Permits needed in connection with the marketing and sales of such Product as currently being
marketed or sold by Borrower, and Borrower has not received any notice from any applicable
Governmental Authority, specifically including the FDA, that such Governmental Authority is
conducting an investigation or review of any such Required Permit or approval or that any such
Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any
order or recommendation stating that such marketing or sales of such Product cease or that such
Product be withdrawn from the marketplace.

(d) Without limiting the generality of Section 5.6 above, (i) there have been no adverse
clinical test results which have or could reasonably be expected to cause a Material Adverse
Change, and (ii) there have been no Product recalls or voluntary Product withdrawals from any
market.

(e) Borrower has not experienced any significant failures in its manufacturing of any Product
such that the amount of such Product successfully manufactured by Borrower in accordance with all
specifications thereof and the required payments related thereto in any month shall decrease
significantly with respect to the quantities of such Product produced in the prior month.

6. AFFIRMATIVE COVENANTS

	 	 	 	 	 
	Borrower covenants and agrees to do all of the following:
	 	6.1	 	 	Organization and Existence; Government Compliance.

	 	 	 	 	 

(a) Maintain its and all its Subsidiaries’ legal existence and good standing in their
respective jurisdictions of formation and maintain qualification in each jurisdiction in which the
failure to so qualify could reasonably be expected to have a Material Adverse Change. Borrower
shall comply, and have each Subsidiary comply, with all Laws, ordinances and regulations to which
it is subject, the noncompliance with which could reasonably be expected to have a Material Adverse
Change.

(b) Obtain and keep in full force and effect, all of the Governmental Approvals necessary for
the performance by Borrower of its obligations under the Loan Documents to which it is a party and
the grant of a security interest to Agent for the ratable benefit of the Lenders, in all of the
Collateral. Borrower shall promptly provide copies of any such obtained Governmental Approvals to
Agent.

(c) In connection with the development, testing, manufacture, marketing or sale of each and
any Product by Borrower, Borrower shall comply fully and completely in all respects with all
Required Permits at all times issued by any Governmental Authority the noncompliance with which
could have a Material Adverse Change, specifically including the FDA, with respect to such
development, testing, manufacture, marketing or sales of such Product by Borrower as such
activities are at any such time being conducted by Borrower.

6.2 Financial Statements, Reports, Certificates.

(a) Deliver to Agent: (i) as soon as available, but no later than forty (40) days after the
last day of each month, a company prepared consolidated balance sheet, income statement and cash
flow statement covering Borrower’s consolidated operations for such month certified by a
Responsible Officer and in a form acceptable to Agent; (ii) as soon as available, but no later than
one hundred twenty (120) days after the last day of Borrower’s fiscal year, audited consolidated
financial statements prepared under GAAP, consistently applied, together with an unqualified
opinion on the financial statements from an independent certified public accounting firm acceptable
to Agent in its reasonable discretion; (iii) as soon as available after approval thereof by
Borrower’s Board of Directors, but no later than sixty (60) days after the last day of Borrower’s
fiscal year, Borrower’s financial projections for current fiscal year as approved by Borrower’s
Board of Directors; (iv) within five (5) days of delivery, copies of all statements, reports and
notices made available to all of Borrower’s security holders or to any holders of Subordinated
Debt; (v) within five (5) days of filing, all reports on Form 10-K, 10-Q and 8-K filed with the
Securities and Exchange Commission or a link thereto on Borrower’s or another website on the
Internet; (vi) a prompt report of any legal actions pending or threatened against Borrower or any
of its Subsidiaries that could result in damages or costs to Borrower or any of its Subsidiaries of
One Hundred Thousand Dollars ($100,000) or more or could result in a Material Adverse Change; and
(vii) budgets, sales projections, operating plans and other financial information reasonably
requested by Agent.

(b) Within forty (40) days after the last day of each month, deliver to Agent with the monthly
financial statements described above, a duly completed Compliance Certificate signed by a
Responsible Officer.

(c) Keep proper books of record and account in accordance with GAAP in which full, true and
correct entries shall be made of all dealings and transactions in relation to its business and
activities. Borrower shall allow, at the sole cost of Borrower, Agent and Lenders to visit and
inspect any of its properties, to examine and make abstracts or copies from any of Borrower’s books
and records, to conduct a collateral audit and analysis of its operations and the Collateral to
verify the amount and age of the accounts, the identity and credit of the respective account
debtors, to review the billing practices of Borrower and to discuss its respective affairs,
finances and accounts with their respective officers, employees and independent public accountants
as often as may reasonably be desired. Notwithstanding the foregoing, such audits shall be
conducted at Borrower’s expense no more often than once every twelve (12) months unless a Default
or Event of Default has occurred and is continuing and otherwise shall be conducted at the sole
cost of Agent and Lenders.

(d) Within ten (10) days of (i) acquiring and/or developing any new Material Intellectual
Property, or (ii) entering or becoming bound by any additional license or sublicense agreement or
other agreement with respect to rights in Material Intellectual Property (other than
over-the-counter software that is commercially available to the public), deliver to Agent an
updated Schedule 5.2(d) reflecting same, and upon any other material change in Borrower’s Material
Intellectual Property from that listed on Schedule 5.2(d). Borrower shall take such steps as Agent
requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary
for (x) all licenses or agreements to be deemed “Collateral” and for Agent to have a security
interest in it that might otherwise be restricted or prohibited by Law or by the terms of any such
license or agreement, whether now existing or entered into in the future, and (y) Agent to have the
ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance
with Agent’s rights and remedies under this Agreement and the other Loan Documents.

(e) If, after the Closing Date, Borrower determines to manufacture, sell, develop, test or
market any new Product, Borrower shall give written notice to Agent as soon as practicable (but in
any event, not more than five (5) days after the Borrower makes such determination) of such
determination (which shall include a brief description of such Product, plus a list of all Required
Permits relating to such new Product (and a copy of such Required Permits if requested by Agent)
and/or Borrower’s manufacture, sale, development, testing or marketing thereof issued or
outstanding as of the date of such notice), along with a copy of an updated Schedule 5.11;
provided, however, that if Borrower shall at any time obtain any new or additional Required Permits
from the FDA, DEA, or parallel state or local authorities, or foreign counterparts of the FDA, DEA,
or parallel state or local authorities, with respect to any Product which has previously been
disclosed to Agent, Borrower shall promptly give written notice to Agent of such new or additional
Required Permits (along with a copy thereof if requested by Agent).

6.3 Inventory; Returns. Keep all Inventory in good and marketable condition, free
from material defects, other than any inventory of drug product that is past its expiration date
and is or will be written off from time to time in accordance with GAAP and applicable laws.
Returns and allowances between Borrower and its Account Debtors shall follow Borrower’s customary
practices as they exist at the Closing Date. Borrower must promptly notify Agent of all returns,
recoveries, disputes and claims that involve more than One Hundred Thousand Dollars ($100,000).

6.4 Taxes; Pensions. Timely file and require each of its Subsidiaries to timely file,
all required tax returns and reports and timely pay, and require each of its Subsidiaries to timely
file, all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by
Borrower and each of its Subsidiaries, except for deferred payment of any taxes contested pursuant
to the terms of Section 5.8 hereof, and shall deliver to Agent, on demand, appropriate certificates
attesting to such payments, and pay all amounts necessary to fund all present pension, profit
sharing and deferred compensation plans in accordance with their terms.

6.5 Insurance. Keep its business and the Collateral insured for risks and in amounts
standard for companies in Borrower’s industry and location and as Agent may reasonably request.
Insurance policies shall be in a form, with companies, and in amounts that are satisfactory to
Agent. All property policies shall have a lender’s loss payable endorsement showing Agent as
lender loss payee and waive subrogation against Agent, and all liability policies shall show, or
have endorsements showing, Agent, as an additional insured. All policies (or the loss payable and
additional insured endorsements) shall provide that the insurer shall endeavor to give Agent at
least thirty (30) days notice before canceling, amending in any material respect, or declining to
renew its policy. At Agent’s request, Borrower shall deliver certified copies of policies and
evidence of all premium payments. Proceeds payable under any policy shall, at Agent’s option, be
payable to Agent on behalf of the Lenders on account of the Obligations. Notwithstanding the
foregoing, (a) so long as no Default or Event of Default has occurred and is continuing, Borrower
shall have the option of applying the proceeds of (X) any casualty policy up to $300,000 in the
aggregate with respect to any inventory loss in any one year, toward the replacement or repair of
destroyed or damaged inventory and (Y) any casualty policy up to $100,000 with respect to any loss
other than loss of inventory, but not exceeding $200,000 in the aggregate for all losses under all
casualty policies in any one year other than as permitted by clause (X) of this sentence, toward
the replacement or repair of destroyed or damaged property; provided that any such replaced or
repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and
(ii) shall be deemed Collateral in which Agent and Lenders have been granted a first priority
security interest, and (b) after the occurrence and during the continuance of a Default or Event of
Default, all proceeds payable under such casualty policy shall, at the option of Agent, be payable
to Agent, for the ratable benefit of the Lenders, on account of the Obligations. If Borrower fails
to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required
proof of payment to third persons and Agent, Agent may make all or part of such payment or obtain
such insurance policies required in this Section 6.5, and take any action under the policies Agent
deems prudent.

6.6 Operating Accounts.

(a) Reserved.

(b) Provide Agent five (5) days prior written notice before establishing any Collateral
Account at or with any bank or financial institution. In addition, for each Collateral Account
that Borrower at any time maintains, Borrower shall cause the applicable bank or financial
institution at or with which any Collateral Account is maintained to execute and deliver a Control
Agreement or other appropriate instrument with respect to such Collateral Account to perfect
Agent’s Lien in such Collateral Account in accordance with the terms hereunder, which Control
Agreement may not be terminated without prior written consent of Agent. The provisions of the
previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes
and other employee wage and benefit payments to or for the benefit of Borrower’s employees and
identified to Agent by Borrower as such.

6.7 Protection of Intellectual Property Rights. Borrower shall own, or be licensed to
use or otherwise have the right to use, all Material Intellectual Property. All Intellectual
Property of Borrower is and shall be fully protected and/or duly and properly registered, filed or
issued in the appropriate office and jurisdictions for such registrations, filings or issuances,
except where the failure to do so would not reasonably be expected to result in a Material Adverse
Change. Borrower shall not become a party to, nor become bound by, any material license or other
agreement with respect to which Borrower is the licensee that prohibits or otherwise restricts
Borrower from granting a security interest in Borrower’s interest in such license or agreement or
other property. Borrower shall at all times conduct its business without infringement or claim of
infringement of any Intellectual Property rights of others. Borrower shall, to the extent it
determines, in the exercise of its reasonable business judgment, that it is prudent to do the
following: (a) protect, defend and maintain the validity and enforceability of its Intellectual
Property; (b) promptly advise Agent in writing of material infringements of its Intellectual
Property; and (c) not allow any Material Intellectual Property to be abandoned, forfeited or
dedicated to the public without Agent’s prior written consent. If Borrower (i) obtains any patent,
registered trademark or servicemark, registered copyright, registered mask work, or any pending
application for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applies for
any patent or the registration of any trademark or servicemark, then Borrower shall concurrently
provide written notice thereof to Agent and shall execute such intellectual property security
agreements and other documents and take such other actions as Agent shall request in its good faith
business judgment to perfect and maintain a first priority perfected security interest in favor of
Agent, for the ratable benefit of Lenders, in such property. If Borrower decides to register any
copyrights or mask works in the United States Copyright Office, Borrower shall: (x) provide Agent
with written notice of Borrower’s intent to register, or registration of, such copyrights or mask
works together with a copy of the application it intends to file or has filed with the United
States Copyright Office (excluding Exhibits thereto) as soon as practicable but no later than three
(3) days after such filing; (y) execute an intellectual property security agreement and such other
documents and take such other actions as Agent may request in its good faith business judgment to
perfect and maintain a first priority perfected security interest in favor of Agent, for the
ratable benefit of the Lenders, in the copyrights or mask works intended to be registered with the
United States Copyright Office; and (z) record such intellectual property security agreement with
the United States Copyright Office contemporaneously with filing the copyright or mask work
application(s) with the United States Copyright Office. Borrower shall promptly provide to Agent
copies of all applications that it files for patents or for the registration of trademarks,
servicemarks, copyrights or mask works, together with evidence of the recording of the intellectual
property security agreement necessary for Agent, for the ratable benefit of the Lenders, to perfect
and maintain a first priority perfected security interest in such property.

6.8 Litigation Cooperation. From the date hereof and continuing through the
termination of this Agreement, make available to Agent, without expense to Agent, Borrower and its
officers, employees and agents and Borrower’s Books, to the extent that Agent may deem them
reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or
against Agent with respect to any Collateral or relating to Borrower.

6.9 Notices of Litigation and Default. Borrower will give prompt written notice to
Agent of any litigation or governmental proceedings pending or threatened (in writing) against
Borrower which would reasonably be expected to have a Material Adverse Change. Without limiting or
contradicting any other more specific provision of this Agreement, promptly (and in any event
within three (3) Business Days) upon Borrower becoming aware of the existence of any Event of
Default or event which, with the giving of notice or passage of time, or both, would constitute an
Event of Default, Borrower shall give written notice to Agent of such occurrence, which such notice
shall include a reasonably detailed description of such Event of Default or event which, with the
giving of notice or passage of time, or both, would constitute an Event of Default.

6.10 Creation/Acquisition of Subsidiaries.  In the event Borrower or any Subsidiary
creates or acquires any Subsidiary, Borrower and such Subsidiary shall promptly notify Agent of the
creation or acquisition of such new Subsidiary and, other than the Meda Royalty Subsidiary, take
all such action as may be reasonably required by Agent to cause each such domestic Subsidiary to
become a co-Borrower hereunder or to guarantee the Obligations of Borrower under the Loan Documents
and, in each case, grant a continuing pledge and security interest in and to the assets of such
Subsidiary (substantially as described on Exhibit A hereto); and Borrower shall grant and pledge to
Agent, for the ratable benefit of the Lenders, a perfected security interest in the stock, units or
other evidence of ownership of each Subsidiary (other than the Meda Royalty Subsidiary).

6.11 Further Assurances.

(a) Execute any further instruments and take further action as Agent reasonably requests to
perfect or continue Agent’s Lien in the Collateral or to effect the purposes of this Agreement.

(b) With the sole exception listed in clause (c) below, deliver to Agent, within five (5) days
after the same are sent or received, copies of all material correspondence, reports, documents and
other filings with any Governmental Authority that could reasonably be expected to have a material
effect on any of the Governmental Approvals material to Borrower’s business or otherwise on the
operations of Borrower or any of its Subsidiaries.

(c) Within five (5) days after receipt of the same, notify Agent about, and, at the request of
Agent, make available for viewing by Agent, copies of all FDA correspondence and correspondence
with analogous non-U.S. or international agencies or regulators received by Borrower.

6.12 Post-Closing Obligations. Borrowers shall complete each of the post closing
obligations and/or deliver to Agent each of the documents, instruments, agreements and information
listed on Schedule 6.12 attached hereto, on or before the date set forth for each such item
thereon, each of which shall be completed or provided in form and substance satisfactory to Agent
and Lenders.

7. NEGATIVE COVENANTS

Borrower shall not do any of the following without the prior written consent of Agent and
Required Lenders:

7.1 Dispositions. Convey, sell, lease, transfer, assign, grant a security in or
otherwise dispose of (collectively, “Transfer”), or permit any of its Subsidiaries to Transfer, all
or any part of its business or property, except for Transfers (a) of Inventory in the Ordinary
Course of Business; (b) of worn-out or obsolete Equipment; (c) in connection with Permitted Liens;
(d) of the Meda Rights and/or, solely if required pursuant to such transaction as a result of the
termination of the Meda AB License Agreement or the discontinuance of the royalty or milestone
payments thereunder, the transfer by EpiCept to the Meda Royalty Subsidiary of the Related
Intellectual Property and Related Contract Rights, in each case pursuant to and subject to the
conditions of a Meda Royalty Monetization Transaction. Without limitation of the foregoing,
Borrower agrees that it shall not grant a security interest or otherwise encumber any of its
Intellectual Property without Agent’s and Lenders’ prior written consent, except as contemplated by
and subject to the conditions of a Meda Royalty Monetization Transaction.

7.2 Changes in Business, Management, Ownership or Business Locations. (a) Engage in
or permit any of its Subsidiaries to engage in any business other than the businesses currently
engaged in by Borrower and such Subsidiary, as applicable, or reasonably related thereto; (b)
liquidate or dissolve; (c) (i) change senior management whereby, within a three-month period, both
John V. Talley and Robert W. Cook cease to be the Chief Executive Officer and Chief Financial
Officer, respectively, or cease to both be active in the management of EpiCept, or (ii) enter into
any transaction or series of related transactions in which the stockholders of Borrower who were
not stockholders immediately prior to the first such transaction own more than forty percent (40%)
of the voting stock of Borrower immediately after giving effect to such transaction or related
series of such transactions (other than by the sale of Borrower’s equity securities in (x) a public
offering or (y) a private placement to one or more institutional private equity or venture capital
investors so long as Borrower identifies to Agent such investors prior to the closing of the
transaction); or (d) add any new offices or business locations, including warehouses (unless such
new offices or business locations contain less than Twenty Five Thousand Dollars ($25,000) in
Borrower’s assets or property and so long as such new offices or business locations do not contain
any Borrower’s Books); (e) change its jurisdiction of organization; (f) change its organizational
structure or type; (g) change its legal name; or (h) change any organizational number (if any)
assigned by its jurisdiction of organization.

7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries
to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to
acquire, all or substantially all of the capital stock or property of another Person; provided,
however, that a Subsidiary of Borrower may merge or consolidate into another Subsidiary that is a
Loan Party or into Borrower, so long as (i) Borrower has provided Agent with prior written notice
of such transaction, (ii) Borrower shall be the surviving legal entity, (iii) Borrower’s tangible
net worth is not thereby reduced, and (iv) as long as no Event of Default is occurring prior
thereto or arises as a result therefrom.

7.4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness, or permit
any Subsidiary to do so, other than Permitted Indebtedness.

7.5 Encumbrance. (a) Create, incur, allow, or suffer any Lien on any of its property,
or assign or convey any right to receive income, including the sale of any Accounts, or permit any
of its Subsidiaries to do so, except for Permitted Liens, (b) permit any Collateral not to be
subject to the first priority security interest granted herein, or (c) enter into any agreement,
document, instrument or other arrangement (except with or in favor of Agent) with any Person which
directly or indirectly prohibits or has the effect of prohibiting Borrower or any Subsidiary from
assigning, mortgaging, pledging, granting a security interest in or upon, or (d) encumbering any of
Borrower’s or any Subsidiary’s Intellectual Property, except as is otherwise permitted in Section
7.1 hereof and the definition of “Permitted Liens” herein.

7.6 Maintenance of Collateral Accounts. Maintain any Collateral Account, except
pursuant to the terms of Section 6.6(b) hereof.

7.7 Distributions; Investments. (a) Pay any dividends (other than dividends payable
solely in common stock) or make any distribution or payment on or redeem, retire or purchase any
capital stock (other than repurchases pursuant to the terms of employee stock purchase plans,
employee restricted stock agreements or similar plans or in connection with any reverse stock split
duly authorized and approved by EpiCept’s Board of Directors and stockholders), or (b) directly or
indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries
to do so.

7.8 Transactions with Affiliates. Directly or indirectly enter into or permit to
exist any material transaction with any Affiliate of Borrower, except for transactions that are in
the Ordinary Course of Business, upon fair and reasonable terms that are no less favorable to
Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person, and
except in connection with a Meda Royalty Monetization Transaction.

7.9 Subordinated Debt. (a) Make or permit any payment on any Subordinated Debt,
except under the terms of the subordination, intercreditor, or other similar agreement to which
such Subordinated Debt is subject, or (b) amend any provision in any document relating to the
Subordinated Debt which would increase the amount thereof or adversely affect the subordination
thereof to Obligations owed to the Lenders.

7.10 Compliance. Become an “investment company” or a company controlled by an
“investment company”, under the Investment Company Act of 1940, as amended or undertake as one of
its important activities extending credit to purchase or carry margin stock (as defined in
Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any
Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a
Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the
Federal Fair Labor Standards Act or violate any other Law or regulation, if the violation could
reasonably be expected to have a Material Adverse Change, or permit any of its Subsidiaries to do
so; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete
termination of, or permit the occurrence of any other event with respect to, any present pension,
profit sharing and deferred compensation plan which could reasonably be expected to result in any
liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its
successors or any other governmental agency.

7.11 Compliance with Anti-Terrorism Laws. Agent hereby notifies Borrower that
pursuant to the requirements of Anti-Terrorism Laws, and Agent’s policies and practices, Agent is
required to obtain, verify and record certain information and documentation that identifies
Borrower and its principals, which information includes the name and address of Borrower and its
principals and such other information that will allow Agent to identify such party in accordance
with Anti-Terrorism Laws. Borrower will not, nor will Borrower permit any Subsidiary or Affiliate
to, directly or indirectly, knowingly enter into any documents, instruments, agreements or
contracts with any Person listed on the OFAC Lists. Borrower shall immediately notify Agent if
Borrower has knowledge that Borrower or any Subsidiary or Affiliate is listed on the OFAC Lists or
(a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and
held over on charges involving money laundering or predicate crimes to money laundering. Borrower
will not, nor will Borrower permit any Subsidiary or Affiliate to, directly or indirectly, (i)
conduct any business or engage in any transaction or dealing with any Blocked Person, including,
without limitation, the making or receiving of any contribution of funds, goods or services to or
for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction
relating to, any property or interests in property blocked pursuant to Executive Order No. 13224,
any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage
in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to
violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism
Law.

8. EVENTS OF DEFAULT

Any one of the following shall constitute an event of default (an “Event of Default”) under
this Agreement:

8.1 Payment Default. Borrower fails to (a) make any payment of principal or interest
on any Credit Extension on its due date, or (b) pay any other Obligations within three (3) Business
Days after such Obligations are due and payable (which three (3) Business Day grace period shall
not apply to payments due on the Maturity Date or the date of acceleration pursuant to Section 9.1
(a) hereof). During the cure period, the failure to cure the payment default is not an Event of
Default (but no Credit Extension will be made during the cure period);

8.2 Covenant Default.

(a) Borrower fails or neglects to perform any obligation in Sections 6.1(c), 6.2, 6.4, 6.5,
6.6, 6.7, 6.10, 6.11 or 6.12 or violates any covenant in Section 7; or

(b) Borrower or any of its Subsidiaries fails or neglects to perform, keep, or observe any
other term, provision, condition, covenant or agreement contained in this Agreement or any Loan
Documents, and as to any default (other than those specified in this Section 8) under such other
term, provision, condition, covenant or agreement that can be cured, has failed to cure the default
within ten (10) days after the occurrence thereof; provided, however, that if the default cannot by
its nature be cured within the ten (10) day period or cannot after diligent attempts by Borrower be
cured within such ten (10) day period, and such default is likely to be cured within a reasonable
time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30)
days) to attempt to cure such default, and within such reasonable time period the failure to cure
the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during
such cure period). Grace periods provided under this Section shall not apply, among other things,
to financial covenants or any other covenants set forth in subsection (a) above;

8.3 Material Adverse Change. A Material Adverse Change occurs;

8.4 Attachment; Levy; Restraint on Business.

(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of
Borrower or of any entity under control of Borrower (including a Subsidiary) on deposit with the
Lenders or any Lender Affiliate, or (ii) a notice of lien, levy, or assessment is filed against any
of Borrower’s assets by any government agency, and the same under subclauses (i) and (ii) hereof
are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through
the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during
any ten (10) day cure period; and

(b) (i) any material portion of Borrower’s assets is attached, seized, levied on, or comes
into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents
Borrower from conducting any part of its business;

8.5 Insolvency. (a) Borrower is unable to pay its debts (including trade debts) as
they become due or otherwise becomes insolvent; (b) Borrower begins an Insolvency Proceeding; or
(c) an Insolvency Proceeding is begun against Borrower and not dismissed or stayed within thirty
(30) days (but no Credit Extensions shall be made while any of the conditions described in clause
(a) exist and/or until any Insolvency Proceeding is dismissed);

8.6 Other Agreements. There is a default in any agreement to which Borrower is a
party with a third party or parties resulting in a right by such third party or parties, whether or
not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Fifty
Thousand Dollars ($50,000) or that could have a Material Adverse Change;

8.7 Judgments. One or more judgments, orders, or decrees for the payment of money in
an amount, individually or in the aggregate, of at least One Hundred Thousand Dollars ($100,000)
(not covered by independent third-party insurance as to which liability has been accepted by such
insurance carrier) shall be rendered against Borrower and shall remain unsatisfied, unvacated, or
unstayed for a period of ten (10) days after the entry thereof, provided, however, that no Credit
Extensions will be made prior to the satisfaction, vacation, or stay of such judgment, order or
decree;

8.8 Misrepresentations. Borrower or any Person acting for Borrower makes any
representation, warranty, or other statement now or later in this Agreement, any Loan Document or
in any writing delivered to Agent and/or the Lenders or to induce Agent and/or the Lenders to enter
this Agreement or any Loan Document, and such representation, warranty, or other statement is
incorrect in any material respect when made;

8.9 Subordinated Debt. A default or breach occurs under any agreement between
Borrower and any creditor of Borrower that signed a subordination, intercreditor, or other similar
agreement with Agent or the Lenders, or any creditor that has signed such an agreement with Agent
or the Lenders breaches any terms of such agreement;

8.10 Governmental Approvals. Any Governmental Approval shall have been (a) revoked,
rescinded, suspended, modified in an adverse manner or not renewed in the Ordinary Course of
Business for a full term, or (b) subject to any decision by a Governmental Authority that
designates a hearing with respect to any applications for renewal of any of such Governmental
Approval or that could result in the Governmental Authority taking any of the actions described in
clause (a) above, and such decision or such revocation, rescission, suspension, modification or
non-renewal (i) has, or could reasonably be expected to have, a Material Adverse Change, or
(ii) adversely affects the legal qualifications of Borrower or any of its Subsidiaries to hold such
Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension,
modification or non-renewal could reasonably be expected to affect the status of or legal
qualifications of Borrower or any of its Subsidiaries to hold any Governmental Approval in any
other jurisdiction;

8.11 Criminal Proceeding. The institution by any Governmental Authority of criminal
proceedings against Borrower;

8.12 Lien Priority. Except as permitted by Agent, any Lien created hereunder or by
any other Loan Document shall at any time fail to constitute a valid and perfected Lien on all of
the Collateral purported to be secured thereby, subject to no prior or equal Lien; or

8.13 Withdrawals, Recalls, Adverse Test Results and Other Matters. (a) The
institution of any proceeding by FDA or similar Governmental Authority to order the withdrawal of
any Product or Product category from the market or to enjoin Borrower or any representative of
Borrower from manufacturing, marketing, selling or distributing any Product or Product category
(other than, after the consummation of the Meda Royalty Monetization Transaction, with respect to a
Product whose sales are the subject of a Meda Royalty Monetization Transaction), which, in Agent’s
reasonable judgment, is likely to cause a Material Adverse Change, (b) the institution of any
action or proceeding by any DEA, FDA, or any other Governmental Authority to revoke, suspend,
reject, withdraw, limit, or restrict any Required Permit held by Borrower or any representative of
Borrower, which, in each case, in Agent’s reasonable judgment, is likely to cause a Material
Adverse Change, (c) the commencement of any enforcement action against Borrower by DEA, FDA, or any
other Governmental Authority, (d) the recall of any Products from the market, the voluntary
withdrawal of any Products from the market, or actions to discontinue the sale of any Products,
which in Agent’s reasonable judgment, is likely to cause a Material Adverse Change, or (e) the
occurrence of adverse test results in connection with a Product which in Agent’s reasonable
judgment, is likely to cause a Material Adverse Change.

9. RIGHTS AND REMEDIES

9.1 Rights and Remedies.

(a) Upon the occurrence and during the continuance of an Event of Default, Agent may, and at
the written direction of any Lender shall, without notice or demand, do any or all of the
following: (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower
declare all Obligations immediately due and payable (but if an Event of Default described in
Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Agent
or the Lenders), or (iii) by notice to Borrower suspend or terminate the obligations, if any, of
the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under
any other agreement between Borrower and Agent and/or the Lenders (but if an Event of Default
described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend
credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower
and Agent and/or the Lenders shall be immediately terminated without any action by Agent or the
Lenders).

(b) Without limiting the rights of Agent and Lenders set forth in Section 9.1(a) above, upon
the occurrence and during the continuance of an Event of Default Agent shall have the right, at the
written direction of the Required Lenders, without notice or demand, to do any or all of the
following:

(i) foreclose upon and/or sell or otherwise liquidate, the Collateral;

(ii) apply to the Obligations any (a) balances and deposits of Borrower that Agent or any
Lender holds or controls, or (b) any amount held or controlled by Agent or any Lender owing to or
for the credit or the account of Borrower; and/or

(iii) commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any
Insolvency Proceeding.

(c) Without limiting the rights of Agent and Lenders set forth in Sections 9.1(a) and (b)
above, upon the occurrence and during the continuance of an Event of Default Agent shall have the
right, without notice or demand, to do any or all of the following:

(i) settle or adjust disputes and claims directly with Account Debtors for amounts on terms
and in any order that Agent considers advisable, notify any Person owing Borrower money of Agent’s
security interest in such funds, and verify the amount of such account;

(ii) make any payments and do any acts it considers necessary or reasonable to protect the
Collateral and/or its security interest in the Collateral. Borrower shall assemble the Collateral
if Agent requests and make it available as Agent designates. Agent may enter premises where the
Collateral is located, take and maintain possession of any part of the Collateral, and pay,
purchase, contest, or compromise any Lien which appears to be prior or superior to its security
interest and pay all expenses incurred. Borrower grants Agent a license to enter and occupy any of
its premises, without charge, to exercise any of Agent’s rights or remedies;

(iii) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or
advertise for sale, the Collateral. Agent is hereby granted a non-exclusive, royalty-free license
or other right to use, without charge, Borrower’s labels, patents, copyrights, mask works, rights
of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter,
or any similar property as it pertains to the Collateral, in completing production of, advertising
for sale, and selling any Collateral and, in connection with Agent’s exercise of its rights under
this Section 9.1, Borrower’s rights under all licenses and all franchise agreements inure to Agent
for the benefit of the Lenders;

(iv) place a “hold” on any account maintained with Agent or the Lenders and/or deliver a
notice of exclusive control, any entitlement order, or other directions or instructions pursuant to
any Control Agreement or similar agreements providing control of any Collateral;

(v) demand and receive possession of Borrower’s Books; and

(vi) subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Agent
under the Loan Documents or at law or equity, including all remedies provided under the Code
(including disposal of the Collateral pursuant to the terms thereof).

Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any
Event of Default, Agent shall have the right to exercise any and all remedies referenced in this
Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent
Circumstance. As used in the immediately preceding sentence, “Exigent Circumstance” means any
event or circumstance that, in the reasonable judgment of Agent, imminently threatens the ability
of Agent to realize upon all or any material portion of the Collateral, such as, without
limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste
thereof, or failure of Borrower after reasonable demand to maintain or reinstate adequate casualty
insurance coverage, or which, in the judgment of Agent, could result in a material diminution in
value of the Collateral.

9.2 Power of Attorney. Borrower hereby irrevocably appoints Agent as its lawful
attorney-in-fact, exercisable upon the occurrence and during the continuance of an Event of
Default, to: (a) endorse Borrower’s name on any checks or other forms of payment or security; (b)
sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account
Debtors; (c) settle and adjust disputes and claims about the Accounts directly with Account
Debtors, for amounts and on terms Agent determines reasonable; (d) make, settle, and adjust all
claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge,
encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based
thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the
Collateral into the name of Agent or a third party as the Code permits. Borrower hereby appoints
Agent as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect
or continue the perfection of Agent’s security interest in the Collateral regardless of whether an
Event of Default has occurred until all Obligations have been satisfied in full and Agent and the
Lenders are under no further obligation to make Credit Extensions hereunder. Agent’s foregoing
appointment as Borrower’s attorney in fact, and all of Agent’s rights and powers, coupled with an
interest, are irrevocable until all Obligations have been fully repaid and performed and Agent’s
and the Lenders’ obligation to provide Credit Extensions terminates.

9.3 Protective Payments. If Borrower fails to obtain the insurance called for by
Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower is
obligated to pay under this Agreement or any other Loan Document, Agent may obtain such insurance
or make such payment, and all amounts so paid by Agent are Lenders’ Expenses and immediately due
and payable, bearing interest at the then highest applicable rate, and secured by the Collateral.
Agent will make reasonable efforts to provide Borrower with notice of Agent obtaining such
insurance at the time it is obtained or within a reasonable time thereafter. No such payments by
Agent are deemed an agreement to make similar payments in the future or Agent’s waiver of any Event
of Default.

9.4 Application of Payments and Proceeds. Notwithstanding anything to the contrary
contained in this Agreement, upon the occurrence and during the continuance of an Event of Default,
(a) Borrower irrevocably waives the right to direct the application of any and all payments at any
time or times thereafter received by Agent from or on behalf of Borrower of all or any part of the
Obligations, and, as between Borrower on the one hand and Agent and Lenders on the other, Agent
shall have the continuing and exclusive right to apply and to reapply any and all payments received
against the Obligations in such manner as Agent may deem advisable notwithstanding any previous
application by Agent, and (b) the proceeds of any sale of, or other realization upon all or any
part of the Collateral shall be applied: first, to the Lenders Expenses; second, to accrued and
unpaid interest on the Obligations (including any interest which, but for the provisions of the
United States Bankruptcy Code, would have accrued on such amounts); third, to the principal amount
of the Obligations outstanding; and fourth, to any other indebtedness or obligations of Borrower
owing to Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered to
Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent
jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be applied in
the numerical order provided until exhausted prior to the application to the next succeeding
category, and (y) each of the Persons entitled to receive a payment in any particular category
shall receive an amount equal to its pro rata share of amounts available to be applied pursuant
thereto for such category. Any reference in this Agreement to an allocation between or sharing by
the Lenders of any right, interest or obligation “ratably,” “proportionally” or in similar terms
shall refer to Pro Rata Share unless expressly provided otherwise. Agent, or if applicable, each
Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the
ratable repayment of each Lender’s portion of any Term Loan and the ratable distribution of
interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a
Lender receiving a scheduled payment shall not be responsible for determining whether the other
Lenders also received their scheduled payment on such date; provided, however, if it is later
determined that a Lender received more than its ratable share of scheduled payments made on any
date or dates, then such Lender shall remit to the Agent or other Lenders such sums as may be
necessary to ensure the ratable payment of such scheduled payments, as instructed by Agent. Any
payment or distribution of any kind or character, whether in cash, properties or securities, shall
be received by a Lender in excess of its ratable share, then the portion of such payment or
distribution in excess of such Lender’s ratable share shall be received by such Lender in trust for
and shall be promptly paid over to the other Lender for application to the payments of amounts due
on the other Lender’s claims. To the extent any payment for the account of Borrower is required to
be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is
necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain
possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for
the Agent and other Lenders for purposes of perfecting Agent’s security interest therein.
Notwithstanding anything to the contrary herein, any warrants issued to the Lenders by
Borrower, the stock issuable thereunder, any equity securities purchased by Lenders, any amounts
paid thereunder, any dividends, and any other rights in connection therewith shall not be subject
to the terms and conditions of this Agreement. Nothing herein shall affect any Lender’s rights
under any such warrants, stock, or other equity securities to administer, manage, transfer, assign,
or exercise such warrants, stock, or other equity securities for its own account.

9.5 Liability for Collateral. So long as Agent and the Lenders comply with reasonable
banking practices regarding the safekeeping of the Collateral in the possession or under the
control of Agent and the Lenders, Agent and the Lenders shall not be liable or responsible for: (a)
the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in
the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or
other Person. Borrower bears all risk of loss, damage or destruction of the Collateral.

9.6 No Waiver; Remedies Cumulative. Agent’s failure, at any time or times, to require
strict performance by Borrower of any provision of this Agreement or any other Loan Document shall
not waive, affect, or diminish any right of Agent thereafter to demand strict performance and
compliance herewith or therewith. No waiver hereunder shall be effective unless signed by Agent
and then is only effective for the specific instance and purpose for which it is given. Agent’s
rights and remedies under this Agreement and the other Loan Documents are cumulative. Agent has
all rights and remedies provided under the Code, by Law, or in equity. Agent’s exercise of one
right or remedy is not an election, and Agent’s waiver of any Event of Default is not a continuing
waiver. Agent’s delay in exercising any remedy is not a waiver, election, or acquiescence.

9.7 Demand Waiver. Borrower waives demand, notice of default or dishonor, notice of
payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise,
settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and
guarantees held by Agent on which Borrower is liable.

9.8 Borrower Liability. Any Borrower may, acting singly, request Term Loans
hereunder.  Each Borrower hereby appoints the other as agent for the other for all purposes
hereunder, including with respect to requesting Term Loans hereunder. Each Borrower hereunder
shall be jointly and severally obligated to repay all Term Loans made hereunder and all other
Obligations, regardless of which Borrower actually receives said Term Loans, as if each Borrower
hereunder directly received all Term Loans.  Each Borrower waives (a) any suretyship defenses
available to it under the Code or any other applicable law, and (b) any right to require the
Lenders or Agent to: (i) proceed against any Borrower or any other person; (ii) proceed against or
exhaust any security; or (iii) pursue any other remedy.  The Lenders or Agent may exercise or not
exercise any right or remedy they have against any Borrower or any security (including the right to
foreclose by judicial or non-judicial sale) without affecting any Borrower’s liability. 
Notwithstanding any other provision of this Agreement or other related document, each Borrower
irrevocably waives all rights that it may have at law or in equity (including, without limitation,
any law subrogating Borrower to the rights of the Lenders and Agent under this Agreement) to seek
contribution, indemnification or any other form of reimbursement from any other Borrower, or any
other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any
payment made by Borrower with respect to the Obligations in connection with this Agreement or
otherwise and all rights that it might have to benefit from, or to participate in, any security for
the Obligations as a result of any payment made by Borrower with respect to the Obligations in
connection with this Agreement or otherwise.  Any agreement providing for indemnification,
reimbursement or any other arrangement prohibited under this Section shall be null and void.  If
any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such
payment in trust for the Lenders and Agent and such payment shall be promptly delivered to Agent
for application to the Obligations, whether matured or unmatured.

10. NOTICES

All notices, consents, requests, approvals, demands, or other communication (collectively,
“Communication”) by any party to this Agreement or any other Loan Document must be in writing and
shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual
receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or
certified mail return receipt requested, with proper postage prepaid; (b) upon transmission, when
sent by electronic mail (if an email address is specified herein) or facsimile transmission; (c)
one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or
(d) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to
be notified and sent to the address, facsimile number, or email address indicated below. Any of
Agent, Lender or Borrower may change its mailing or electronic mail address or facsimile number by
giving the other party written notice thereof in accordance with the terms of this Section 10.

If to Borrower:

EpiCept Corporation

777 Old Saw Mill River Road

Tarrytown, NY 10591

Attention: Robert W. Cook, Chief Financial Officer

Fax: (914) 606-3501

E-Mail: rcook@epicept.com

with a copy to:

Eilenberg & Krause LLP

11 East 44th Street

New York, NY 10017

Attention: Adam D. Eilenberg, Esq.

Fax: (212) 986-2399

E-Mail: ade@eklawllp.com

If to Agent or Lenders:

MidCap Funding III, LLC

7735 Old Georgetown Road, Suite 400

Bethesda, Maryland 20814

Attention: Portfolio Management- Life Sciences

Fax: (301) 941-1450

E-Mail:

with a copy to:

Midcap Financial, LLC

7735 Old Georgetown Road, Suite 400

Bethesda, Maryland 20814

Attention: General Counsel

Fax: (301) 941-1450

E-Mail:

11. CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER

THIS AGREEMENT, EACH SECURED PROMISSORY NOTE AND EACH OTHER LOAN DOCUMENT, AND ALL MATTERS
RELATING HERETO OR THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR
OTHERWISE), SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS
OF THE STATE OF MARYLAND, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES. NOTWITHSTANDING THE
FOREGOING, AGENT AND LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST
BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH AGENT AND LENDERS (IN
ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE
COLLATERAL OR TO OTHERWISE ENFORCE AGENT’S AND LENDERS’ RIGHTS AGAINST BORROWER OR ITS PROPERTY.
BORROWER EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT
COMMENCED IN ANY SUCH COURT, AND BORROWER HEREBY WAIVES ANY OBJECTION THAT IT MAY HAVE BASED UPON
LACK OF PERSONAL JURISDICTION, IMPROPER VENUE, OR FORUM NON CONVENIENS AND HEREBY CONSENTS TO THE
GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT. BORROWER HEREBY
WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINTS, AND OTHER PROCESS ISSUED IN SUCH ACTION OR SUIT
AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS, AND OTHER PROCESS MAY BE MADE BY REGISTERED OR
CERTIFIED MAIL ADDRESSED TO BORROWER AT THE ADDRESS SET FORTH IN SECTION 10 OF THIS AGREEMENT AND
THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER TO OCCUR OF BORROWER’S ACTUAL
RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID.

TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, AGENT AND LENDERS EACH WAIVE
THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS
AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF
DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS
AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.

Borrower, Agent and each Lender agree that each Term Loan (including those made on the Closing
Date) shall be deemed to be made in, and the transactions contemplated hereunder and in any other
Loan Document shall be deemed to have been performed in, the State of Maryland.

12. GENERAL PROVISIONS

12.1 Successors and Assigns. This Agreement binds and is for the benefit of the
successors and permitted assigns of each party. Borrower may not assign this Agreement or any
rights or obligations under it without Agent’s prior written consent (which may be granted or
withheld in Agent’s discretion). Any Lender may at any time assign to one or more Eligible
Assignees all or any portion of such Lender’s Loan, together with all related obligations of such
Lender hereunder. Borrower and Agent shall be entitled to continue to deal solely and directly
with such Lender in connection with the interests so assigned until Agent shall have received and
accepted an effective assignment agreement in form and substance acceptable to Agent, executed,
delivered and fully completed by the applicable parties thereto, and shall have received such other
information regarding such Eligible Assignee as Agent reasonably shall require. Notwithstanding
anything set forth in this Agreement to the contrary, any Lender may at any time pledge or assign a
security interest in all or any portion of its rights under this Agreement to secure obligations of
such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank;
provided, however, that no such pledge or assignment shall release such Lender from any of its
obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.

12.2 Indemnification.

(a) Borrower agrees to indemnify, defend and hold Agent and the Lenders and their respective
directors, officers, employees, agents, attorneys, or any other Person affiliated with or
representing Agent or the Lenders (each, an “Indemnified Person”) harmless against: (i) all
obligations, demands, claims, and liabilities (collectively, “Claims”) asserted by any other party
in connection with the transactions contemplated by the Loan Documents; and (ii) all losses or
Lenders’ Expenses incurred, or paid by Indemnified Person from, following, or arising from
transactions between Agent, and/or the Lenders and Borrower (including reasonable attorneys’ fees
and expenses), except for Claims and/or losses directly caused by such Indemnified Person’s gross
negligence or willful misconduct (collectively, the “Indemnified Liabilities”).

(b) Borrower hereby further indemnifies, defends and holds each Indemnified Person harmless
from and against any and all liabilities, obligations, losses, damages, penalties, actions,
judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever
(including the fees and disbursements of counsel for such Indemnitee) in connection with any
investigative, response, remedial, administrative or judicial matter or proceeding, whether or not
such Indemnified Person shall be designated a party thereto and including any such proceeding
initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers,
environmental consultants and similar technical personnel and any commission, fee or compensation
claimed by any broker (other than any broker retained by Agent or Lenders) asserting any right to
payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted
against such Indemnified Person as a result of or in connection with the transactions contemplated
hereby and the use or intended use of the proceeds of the loan proceeds.

(c) To the extent that the undertaking set forth in this Section 12.2 may be unenforceable,
Borrower shall contribute the maximum portion which it is permitted to pay and satisfy under
applicable law to the payment and satisfaction of all such indemnified liabilities incurred by the
Indemnitees or any of them.

12.3 Time of Essence. Time is of the essence for the performance of all Obligations
in this Agreement.

12.4 Severability of Provisions. Each provision of this Agreement is severable from
every other provision in determining the enforceability of any provision.

12.5 Correction of Loan Documents. Agent and the Lenders may correct patent errors
and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement
of the parties.

12.6 Integration. This Agreement and the Loan Documents represent the entire
agreement about this subject matter and supersede prior negotiations or agreements. All prior
agreements, understandings, representations, warranties, and negotiations between the parties about
the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan
Documents.

12.7 Counterparts. This Agreement may be executed in any number of counterparts and
by different parties on separate counterparts, each of which, when executed and delivered, is an
original, and all taken together, constitute one Agreement.

12.8 Survival. All covenants, representations and warranties made in this Agreement
continue in full force until this Agreement has terminated pursuant to its terms and all
Obligations (other than inchoate indemnity obligations and any other obligations which, by their
terms, are to survive the termination of this Agreement) have been satisfied. The obligation of
Borrower in Section 12.2 to indemnify each Lender and Agent shall survive until the statute of
limitations with respect to such claim or cause of action shall have run.

12.9 Confidentiality. In handling any confidential information of Borrower, the
Lenders and Agent shall exercise the same degree of care that it exercises for its own proprietary
information, but disclosure of information may be made: (a) to the Lenders’ and Agent’s
Subsidiaries or Affiliates; (b) to prospective transferees or purchasers of any interest in the
Credit Extensions (provided, however, the Lenders and Agent shall use their best efforts to obtain
a customary agreement consistent with industry practice from such prospective transferee’s or
purchaser’s agreement regarding confidentiality, the terms of which shall be reasonably similar to
this provision); (c) as required by Law, regulation, subpoena, or other order; (d) to regulators or
as otherwise required in connection with an examination or audit; (e) as Agent considers
appropriate in exercising remedies under the Loan Documents; and (f) to third party service
providers of the Lenders and/or Agent so long as such service providers have executed a
confidentiality agreement with the Lenders and Agent with terms no less restrictive than those
contained herein. Confidential information does not include information that either: (i) is in the
public domain or in the Lenders’ and/or Agent’s possession when disclosed to the Lenders and/or
Agent, or becomes part of the public domain after disclosure to the Lenders and/or Agent; or (ii)
is disclosed to the Lenders and/or Agent by a third party, if the Lenders and/or Agent does not
know that the third party is prohibited from disclosing the information. Agent and/or Lenders may
use confidential information for any purpose, including, without limitation, for the development of
client databases, reporting purposes, and market analysis, so long as Agent and/or Lenders, as
applicable, do not disclose Borrower’s identity or the identity of any person associated with
Borrower unless otherwise expressly permitted by this Agreement. The provisions of the immediately
preceding sentence shall survive the termination of this Agreement. The agreements
provided under this Section 12.9 supersede all prior agreements, understanding, representations,
warranties, and negotiations between the parties about the subject matter of this Section 12.9.

12.10 Right of Set Off. Borrower hereby grants to Agent and to each Lender, a lien,
security interest and right of set off as security for all Obligations to Agent and each Lender
hereunder, whether now existing or hereafter arising upon and against all deposits, credits,
collateral and property, now or hereafter in the possession, custody, safekeeping or control of
Agent or the Lenders or any entity under the control of Agent or the Lenders (including a Agent
affiliate) or in transit to any of them. At any time after the occurrence and during the
continuance of an Event of Default, without demand or notice, Agent or the Lenders may set off the
same or any part thereof and apply the same to any liability or obligation of Borrower even though
unmatured and regardless of the adequacy of any other collateral securing the Obligations. ANY AND
ALL RIGHTS TO REQUIRE AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL
WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH
DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY
WAIVED.

12.11 Reserved.

12.12 Amendments.

(a) Unless otherwise specifically set forth in this Agreement, no amendment, modification,
termination or waiver of any provision of this Agreement or any other Loan Document, no approval or
consent thereunder, or any consent to any departure by Borrower therefrom, shall in any event be
effective unless the same shall be in writing and signed by Borrower, Agent and the Required
Lenders, provided, however, that

(i) no such amendment, waiver or other modification that would have the effect of increasing
or reducing a Lender’s Term Loan Commitment or Commitment Percentage shall be effective as to such
Lender without such Lender’s written consent;

(ii) no such amendment, waiver or modification that would affect the rights and duties of
Agent shall be effective without Agent’s written consent or signature;

(iii) no such amendment, waiver or other modification shall, unless signed by all the Lenders
directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with
respect to any Term Loan or forgive any principal, interest (other than default interest) or fees
(other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive,
any payment of principal of any Term Loan or of interest on any Term Loan (other than default
interest) or any fees provided for hereunder (other than late charges or for any termination of any
commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders
which shall be required for Lenders to take any action hereunder; (D) release all or substantially
all or any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of
all or substantially all or any material portion of the Collateral or release any Guarantor of all
or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each
case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement
or the other Loan Documents (including in connection with any disposition permitted hereunder); (E)
amend, waive or otherwise modify this Section 12.12 or the definitions of the terms used in this
Section 12.12 insofar as the definitions affect the substance of this Section 12.12; (F) consent to
the assignment, delegation or other transfer by any Borrower or any Guarantor of any of its rights
and obligations under any Loan Document or release Borrower or any Guarantor of its payment
obligations under any Loan Document, except, in each case with respect to this clause (F),
pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the
provisions of Section 9.4 or amend any of the definitions Pro Rata Share, Term Loan Commitment,
Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees,
payments, setoffs or proceeds of Collateral hereunder; (H) subordinate the Liens granted in favor
of Agent securing the Obligations; or (I) amend any of the provisions of Section 12.10. It is
hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment,
waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G)
and (H) of the preceding sentence;

(iv) the provisions of the foregoing clauses (i), (ii) and (iii) are subject to the provisions
of any interlender or agency agreement among the Agent and Lenders pursuant to which any Lender may
agree to give its consent in connection with any amendment, waiver or modification of the Loan
Documents only in the event of the unanimous agreement of all Lenders.

(b) Other than as expressly provided for in Section 12.12(a)(i) through (iii) above, Agent
may, if requested by the Required Lenders, from time to time designate covenants in this Agreement
less restrictive by notification to a representative of the Borrower.

12.13 Publicity. Borrower will not directly or indirectly publish, disclose or
otherwise use in any public disclosure, advertising material, promotional material, press release
or interview, any reference to the name, logo or any trademark of Agent or any Lender or any of
their Affiliates or any reference to this Agreement or the financing evidenced hereby, in any case
except as required by applicable Law, subpoena or judicial or similar order, in which case Borrower
shall endeavor to give Agent prior written notice of such publication or other disclosure. Each
Lender and Borrower hereby authorizes each Lender to publish the name of such Lender and Borrower,
the existence of the financing arrangements referenced under this Agreement, the primary purpose
and/or structure of those arrangements, the amount of credit extended under each facility, the
title and role of each party to this Agreement, and the total amount of the financing evidenced
hereby in any “tombstone”, comparable advertisement or press release which such Lender elects to
submit for publication. In addition, each Lender and Borrower agrees that each Lender may provide
lending industry trade organizations with information necessary and customary for inclusion in
league table measurements after the Closing Date. With respect to any of the foregoing, such
authorization shall be subject to such Lender providing Borrower and the other Lenders with an
opportunity to review and confer with such Lender regarding, and approve, the contents of any such
tombstone, advertisement or information, as applicable, prior to its initial submission for
publication, but subsequent publications of the same tombstone, advertisement or information shall
not require Borrower’s approval.

12.14 No Strict Construction. The parties hereto have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or
interpretation arises, this Agreement shall be construed as if drafted jointly by the parties
hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement.

13. AGENT

13.1 Appointment and Authorization of Agent. Each Lender hereby irrevocably appoints,
designates and authorizes Agent to take such action on its behalf under the provisions of this
Agreement and each other Loan Document and to exercise such powers and perform such duties as are
expressly delegated to it by the terms of this Agreement or any other Loan Document, together with
such powers as are reasonably incidental thereto. Notwithstanding any provision to the contrary
contained elsewhere herein or in any other Loan Document, Agent shall not have any duties or
responsibilities, except those expressly set forth herein, nor shall Agent have or be deemed to
have any fiduciary relationship with any Lender or participant, and no implied covenants,
functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement
or any other Loan Document or otherwise exist against Agent. Without limiting the generality of the
foregoing sentence, the use of the term “agent” herein and in the other Loan Documents with
reference to Agent is not intended to connote any fiduciary or other implied (or express)
obligations arising under agency doctrine of any applicable Law. Instead, such term is used merely
as a matter of market custom, and is intended to create or reflect only an administrative
relationship between independent contracting parties.

13.2 Delegation of Duties. Agent may execute any of its duties under this Agreement or
any other Loan Document by or through its, or its Affiliates’, agents, employees or
attorneys-in-fact and shall be entitled to obtain and rely upon the advice of counsel and other
consultants or experts concerning all matters pertaining to such duties. Agent shall not be
responsible for the negligence or misconduct of any agent or attorney-in-fact that it selects in
the absence of gross negligence or willful misconduct.

13.3 Liability of Agent. Except as otherwise provided herein, no Agent-Related Person
shall (a) be liable for any action taken or omitted to be taken by any of them under or in
connection with this Agreement or any other Loan Document or the transactions contemplated hereby
(except for its own gross negligence or willful misconduct in connection with its duties expressly
set forth herein), or (b) be responsible in any manner to any Lender or participant for any
recital, statement, representation or warranty made by Borrower or any officer thereof, contained
herein or in any other Loan Document, or in any certificate, report, statement or other document
referred to or provided for in, or received by Agent under or in connection with, this Agreement or
any other Loan Document, or the validity, effectiveness, genuineness, enforceability or sufficiency
of this Agreement or any other Loan Document, or for any failure of Borrower or any other party to
any Loan Document to perform its obligations hereunder or thereunder. No Agent-Related Person shall
be under any obligation to any Lender or participant to ascertain or to inquire as to the
observance or performance of any of the agreements contained in, or conditions of, this Agreement
or any other Loan Document, or to inspect the properties, books or records of Borrower or any
Affiliate thereof.

13.4 Reliance by Agent. Agent shall be entitled to rely, and shall be fully protected
in relying, upon any writing, communication, signature, resolution, representation, notice,
consent, certificate, affidavit, letter, telegram, facsimile, telex or telephone message,
electronic mail message, statement or other document or conversation believed by it to be genuine
and correct and to have been signed, sent or made by the proper Person or Persons, and upon advice
and statements of legal counsel (including counsel to Borrower), independent accountants and other
experts selected by Agent. Agent shall be fully justified in failing or refusing to take any action
under any Loan Document unless it shall first receive such advice or concurrence of all Lenders as
it deems appropriate and, if it so requests, it shall first be indemnified to its satisfaction by
the Lenders against any and all liability and expense which may be incurred by it by reason of
taking or continuing to take any such action. Agent shall in all cases be fully protected in
acting, or in refraining from acting, under this Agreement or any other Loan Document in accordance
with a request or consent of all Lenders and such request and any action taken or failure to act
pursuant thereto shall be binding upon all the Lenders.

13.5 Notice of Default. Agent shall not be deemed to have knowledge or notice of the
occurrence of any Default and/or Event of Default, unless Agent shall have received written notice
from a Lender or Borrower, describing such default or Event of Default. Agent will notify the
Lenders of its receipt of any such notice. Agent shall take such action with respect to an Event of
Default as may be directed in writing by the Required Lenders in accordance with Section 9(a);
provided, however, that while an Event of Default has occurred and is continuing, Agent may (but
shall not be obligated to) take such action, or refrain from taking such action, with respect to
such Event of Default as Agent shall deem advisable or in the best interest of the Lenders,
including without limitation, satisfaction of other security interests, liens or encumbrances on
the Collateral not permitted under the Loan Documents, payment of taxes on behalf of Borrower,
payments to landlords, warehouseman, bailees and other Persons in possession of the Collateral and
other actions to protect and safeguard the Collateral, and actions with respect to insurance claims
for casualty events affecting Borrower and/or the Collateral.

13.6 Credit Decision; Disclosure of Information by Agent. Each Lender acknowledges
that no Agent-Related Person has made any representation or warranty to it, and that no act by
Agent hereafter taken, including any consent to and acceptance of any assignment or review of the
affairs of Borrower or any Affiliate thereof, shall be deemed to constitute any representation or
warranty by any Agent-Related Person to any Lender as to any matter, including whether
Agent-Related Persons have disclosed material information in their possession. Each Lender
represents to Agent that it has, independently and without reliance upon any Agent-Related Person
and based on such documents and information as it has deemed appropriate, made its own appraisal
of, and investigation into, the business, prospects, operations, property, financial and other
condition and creditworthiness of Borrower and its respective Subsidiaries, and all applicable bank
or other regulatory Laws relating to the transactions contemplated hereby, and made its own
decision to enter into this Agreement and to extend credit to Borrower hereunder. Each Lender also
represents that it will, independently and without reliance upon any Agent-Related Person and based
on such documents and information as it shall deem appropriate at the time, continue to make its
own credit analysis, appraisals and decisions in taking or not taking action under this Agreement
and the other Loan Documents, and to make such investigations as it deems necessary to inform
itself as to the business, prospects, operations, property, financial and other condition and
creditworthiness of Borrower. Except for notices, reports and other documents expressly required to
be furnished to the Lenders by Agent herein, Agent shall not have any duty or responsibility to
provide any Lender with any credit or other information concerning the business, prospects,
operations, property, financial and other condition or creditworthiness of Borrower or any of its
Affiliates which may come into the possession of any Agent-Related Person.

13.7 Indemnification of Agent. Whether or not the transactions contemplated hereby are
consummated, each Lender shall, severally and pro rata based on its respective Pro Rata Share,
indemnify upon demand each Agent-Related Person (to the extent not reimbursed by or on behalf of
Borrower and without limiting the obligation of Borrower to do so), and hold harmless each
Agent-Related Person from and against any and all Indemnified Liabilities (which shall not include
legal expenses of Agent incurred in connection with the closing of the transactions contemplated by
this Agreement) incurred by it; provided, however, that no Lender shall be liable for the payment
to any Agent-Related Person of any portion of such Indemnified Liabilities to the extent determined
in a judgment by a court of competent jurisdiction to have resulted from such Agent-Related
Person’s own gross negligence or willful misconduct; provided, however, that no action taken in
accordance with the directions of the Required Lenders shall be deemed to constitute gross
negligence or willful misconduct for purposes of this Section 13.7. Without limitation of the
foregoing, each Lender shall, severally and pro rata based on its respective Pro Rata Share,
reimburse Agent upon demand for its ratable share of any costs or out-of-pocket expenses (including
Lenders’ Expenses incurred after the closing of the transactions contemplated by this Agreement)
incurred by Agent (in its capacity as Agent, and not as a Lender) in connection with the
preparation, execution, delivery, administration, modification, amendment or enforcement (whether
through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or
responsibilities under, this Agreement, any other Loan Document, or any document contemplated by or
referred to herein, to the extent that Agent is not reimbursed for such expenses by or on behalf of
Borrower. The undertaking in this Section 13.7 shall survive the payment in full of the
Obligations, the termination of this Agreement and the resignation of Agent.

13.8 Agent in its Individual Capacity. With respect to its Credit Extensions, MidCap
shall have the same rights and powers under this Agreement as any other Lender and may exercise
such rights and powers as though it were not Agent, and the terms “Lender” and “Lenders” include
MidCap in its individual capacity.

13.9 Successor Agent.

(a) Agent may at any time assign its rights, powers, privileges and duties hereunder to (i)
another Lender, or (ii) any Person to whom Agent, in its capacity as a Lender, has assigned (or
will assign, in conjunction with such assignment of agency rights hereunder) 50% or more of its
Loan, in each case without the consent of the Lenders or Borrowers. Following any such assignment,
Agent shall give notice to the Lenders and Borrowers. An assignment by Agent pursuant to this
subsection (a) shall not be deemed a resignation by Agent for purposes of subsection (b) below.

(b) Without limiting the rights of Agent to designate an assignee pursuant to subsection (a)
above, Agent may at any time give notice of its resignation to the Lenders and Borrowers. Upon
receipt of any such notice of resignation, Required Lenders shall have the right to appoint a
successor Agent. If no such successor shall have been so appointed by Required Lenders and shall
have accepted such appointment within ten (10) Business Days after the retiring Agent gives notice
of its resignation, then the retiring Agent may, on behalf of the Lenders, appoint a successor
Agent; provided, however, that if Agent shall notify Borrowers and the Lenders that no Person has
accepted such appointment, then such resignation shall nonetheless become effective in accordance
with such notice from Agent that no Person has accepted such appointment and, from and following
delivery of such notice, (i) the retiring Agent shall be discharged from its duties and obligations
hereunder and under the other Loan Documents, and (ii) all payments, communications and
determinations provided to be made by, to or through Agent shall instead be made by or to each
Lender directly, until such time as Required Lenders appoint a successor Agent as provided for
above in this subsection (b).

(c) Upon (i) an assignment permitted by subsection (a) above, or (ii) the acceptance of a
successor’s appointment as Agent pursuant to subsection (b) above, such successor shall succeed to
and become vested with all of the rights, powers, privileges and duties of the retiring (or
retired) Agent, and the retiring Agent shall be discharged from all of its duties and obligations
hereunder and under the other Loan Documents (if not already discharged therefrom as provided above
in this subsection (c)). The fees payable by Borrowers to a successor Agent shall be the same as
those payable to its predecessor unless otherwise agreed between Borrower and such successor.
After the retiring Agent’s resignation hereunder and under the other Financing Documents, the
provisions of this Section 13 shall continue in effect for the benefit of such retiring Agent and
its sub-agents in respect of any actions taken or omitted to be taken by any of them while the
retiring Agent was acting or was continuing to act as Agent.

13.10 Agent May File Proofs of Claim. In case of the pendency of any receivership,
insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other
judicial proceeding relative to Borrower, Agent (irrespective of whether the principal of any Loan,
shall then be due and payable as herein expressed or by declaration or otherwise and irrespective
of whether Agent shall have made any demand on Borrower) shall be entitled and empowered, by
intervention in such proceeding or otherwise:

(a) to file and prove a claim for the whole amount of the principal and interest owing and
unpaid in respect of the Credit Extensions and all other Obligations that are owing and unpaid and
to file such other documents as may be necessary or advisable in order to have the claims of the
Lenders and Agent (including any claim for the reasonable compensation, expenses, disbursements and
advances of the Lenders and Agent and their respective agents and counsel and all other amounts due
the Lenders and Agent allowed in such judicial proceeding); and

(b) to collect and receive any monies or other property payable or deliverable on any such
claims and to distribute the same;

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official
in any such judicial proceeding is hereby authorized by each Lender to make such payments to Agent
and, in the event that Agent shall consent to the making of such payments directly to the Lenders,
to pay to Agent any amount due for the reasonable compensation, expenses, disbursements and
advances of Agent and its agents and counsel, and any other amounts due Agent under Section 2.4(d).
To the extent that Agent fails timely to do so, each Lender may file a claim relating to such
Lender’s claim.

13.11 Collateral and Guaranty Matters. The Lenders irrevocably authorize Agent, at its
option and in its discretion, to release any Guarantor and any Lien on any Collateral granted to or
held by Agent under any Loan Document (a) upon the date that all Obligations due hereunder have
been fully and indefeasibly paid in full and no Term Loan Commitments or other obligations of any
Lender to provide funds to Borrower under this Agreement remain outstanding, (b) that is
transferred or to be transferred as part of or in connection with any Transfer permitted hereunder
or under any other Loan Document, or (c) as approved in accordance with Section 12.11. Upon request
by Agent at any time, all Lenders will confirm in writing Agent’s authority to release its interest
in particular types or items of Property, pursuant to this Section 13.11.

13.12 Cooperation of Borrower. If necessary, Borrower agrees to (a) execute any
documents (including new Secured Promissory Notes) reasonably required to effectuate and
acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with
Section 12.1, (b) make Borrower’s management available to meet with Agent and prospective
participants and assignees of Term Loan Commitments or Credit Extensions and (c) assist Agent or
the Lenders in the preparation of information relating to the financial affairs of Borrower as any
prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may request.
Subject to the provisions of Section 12.9 Borrower authorizes each Lender to disclose to any
prospective participant or assignee of a Term Loan Commitment, any and all information in such
Lender’s possession concerning Borrower and its financial affairs which has been delivered to such
Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such
Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation of Borrower
prior to entering into this Agreement.

14. DEFINITIONS

As used in this Agreement, the following terms have the following meanings:

“Account” means any “account”, as defined in the Code, with such additions to such term as may
hereafter be made, and includes, without limitation, all accounts receivable and other sums owing
to Borrower.

“Account Debtor” means any “account debtor”, as defined in the Code, with such additions to
such term as may hereafter be made.

“Affiliate” means, with respect to any Person, a Person that owns or controls directly or
indirectly the Person, any Person that controls or is controlled by or is under common control with
the Person, and each of that Person’s senior executive officers, directors, partners and, for any
Person that is a limited liability company, that Person’s managers and members.

“Agent” means, MidCap, not in its individual capacity, but solely in its capacity as agent on
behalf of and for the benefit of the Lenders.

“Agent-Related Person” means the Agent, together with its Affiliates, and the officers,
directors, employees, agents, advisors, auditors and attorneys-in-fact of such Persons; provided,
however, that no Agent-Related Person shall be an Affiliate of Borrower.

“Agreement” has the meaning given it in the preamble of this Agreement.

“Amortization Date” means (a) December 1, 2011, or (b) if, on or before December 1, 2011,
Borrower shall have received net cash proceeds in an amount not less than ten million and no/100
dollars ($10,000,000.00) pursuant to a Qualifying Transaction, March 1, 2012.

“Anti-Terrorism Laws” means any Laws relating to terrorism or money laundering, including
Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the Laws comprising
or implementing the Bank Secrecy Act, and the Laws administered by OFAC.

“Approved Fund” means any (a) investment company, fund, trust, securitization vehicle or
conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in
commercial loans and similar extensions of credit in the Ordinary Course of Business, or (b) any
Person (other than a natural person) which temporarily warehouses loans for any Lender or any
entity described in the preceding clause (a) and that, with respect to each of the preceding
clauses (a) and (b), is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender or
(iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural
person) that administers or manages a Lender.

“Base LIBOR Rate” means, for any Interest Period, the rate per annum, determined by Agent in
accordance with its customary procedures, and utilizing such electronic or other quotation sources
as it considers appropriate (rounded upwards, if necessary, to the next 1/100%), to be the rate at
which Dollar deposits (for delivery on the first day of such Interest Period or, if such day is not
a Business Day, on the preceding Business Day) in the amount of One Million Dollars ($1,000,000)
are offered to major banks in the London interbank market on or about 11:00 a.m. (New York time)
two (2) Business Days prior to the commencement of such Interest Period, for a term comparable to
such Interest Period, which determination shall be conclusive in the absence of manifest error.

“Blocked Person” means: (a) any Person listed in the annex to, or is otherwise subject to the
provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on
behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of,
Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or
otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits,
threatens or conspires to commit or supports “terrorism” as defined in Executive Order No. 13224,
or (e) a Person that is named a “specially designated national” or “blocked person” on the most
current list published by OFAC or other similar list.

“Borrower” has the meaning given it in the preamble of this Agreement.

“Borrower’s Books” means all of Borrower’s books and records, including ledgers, federal and
state tax returns, records regarding Borrower’s assets or liabilities, the Collateral, business
operations or financial condition, and all computer programs or storage or any equipment containing
such information.

“Borrowing Resolutions” means, with respect to any Person, those resolutions adopted by such
Person’s Board of Directors and delivered by such Person to Agent approving the Loan Documents to
which such Person is a party and the transactions contemplated thereby, together with a certificate
executed by its secretary on behalf of such Person certifying that (a) such Person has the
authority to execute, deliver, and perform its obligations under each of the Loan Documents to
which it is a party, (b) that attached as Exhibit A to such certificate is a true, correct, and
complete copy of the resolutions then in full force and effect authorizing and ratifying the
execution, delivery, and performance by such Person of the Loan Documents to which it is a party,
(c) the name(s) of the Person(s) authorized to execute the Loan Documents on behalf of such Person,
together with a sample of the true signature(s) of such Person(s), and (d) that Agent and the
Lenders may conclusively rely on such certificate unless and until such Person shall have delivered
to Agent a further certificate canceling or amending such prior certificate.

“Business Day” means any day that is not a Saturday, Sunday or a day on which Agent is closed.

“Cash Equivalents” means (a) marketable direct obligations issued or unconditionally
guaranteed by the United States or any agency or any State thereof having maturities of not more
than one (1) year from the date of acquisition, (b) commercial paper maturing no more than one (1)
year after its creation and having the highest rating from either Standard & Poor’s Ratings Group
or Moody’s Investors Service, Inc., (c) certificates of deposit issued maturing no more than one
(1) year after issue, and (d) money market funds at least ninety-five percent (95%) of
the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (b)
of this definition.. For the avoidance of doubt, the direct purchase by Borrower, co-borrower, or
any subsidiary of Borrower of any Auction Rate Securities, or purchasing participations in, or
entering into any type of swap or other derivative transaction, or otherwise holding or engaging in
any ownership interest in any type of Auction Rate Security by Borrower, co-borrower, or any
subsidiary of Borrower shall be conclusively determined by the Lenders as an ineligible Cash
Equivalent, and any such transaction shall expressly violate each other provision of this agreement
governing Permitted Investments. Notwithstanding the foregoing, Cash Equivalents does not include,
and each Borrower and Subsidiary is prohibited from purchasing, purchasing participations in,
entering into any type of swap or other equivalent derivative transaction, or otherwise holding or
engaging in any ownership interest in any type of debt instrument, including, without limitation,
any corporate or municipal bonds with a long-term nominal maturity for which the interest rate is
reset through a dutch auction and more commonly referred to as an auction rate security.

“Change in Control” means any event, transaction, or occurrence as a result of which (a) any
“person” (as such term is defined in Sections 3(a)(9) and 13(d)(3) of the Exchange Act), other than
a trustee or other fiduciary holding securities under an employee benefit plan of Borrower, is or
becomes a beneficial owner (within the meaning Rule 13d-3 promulgated under the Exchange Act),
directly or indirectly, of securities of Borrower, representing twenty-five percent (25%) or more
of the combined voting power of Borrower’s then outstanding securities; or (b) during any period of
twelve consecutive calendar months, individuals who at the beginning of such period constituted the
Board of Directors of Borrower (together with any new directors whose election by the Board of
Directors of Borrower was approved by a vote of not less than two-thirds of the directors then
still in office who either were directions at the beginning of such period or whose election or
nomination for election was previously so approved) cease for any reason other than death or
disability to constitute a majority of the directors then in office.

“Claims” has the meaning given it in Section 12.2.

“Closing Date” has the meaning given it in the preamble of this Agreement.

“Code” means the Uniform Commercial Code in effect on the date hereof, as the same may, from
time to time, be enacted and in effect in the State of Maryland; provided, however, that to the
extent that the Code is used to define any term herein or in any Loan Document and such term is
defined differently in different Articles or Divisions of the Code, the definition of such term
contained in Article or Division 9 shall govern; and provided, further, that in the event that, by
reason of mandatory provisions of Law, any or all of the attachment, perfection, or priority of, or
remedies with respect to, Agent’s Lien on any Collateral is governed by the Uniform Commercial Code
in effect in a jurisdiction other than the State of Maryland, the term “Code” shall mean the
Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of
the provisions thereof relating to such attachment, perfection, priority, or remedies and for
purposes of definitions relating to such provisions.

“Collateral” means all property, now existing or hereafter acquired, mortgaged or pledged to,
or purported to be subjected to a Lien in favor of Agent, for the benefit of Agent and Lenders,
pursuant to this Agreement and the other Loan Documents, including, without limitation, all of the
property described in Exhibit A hereto.

“Collateral Account” means any Deposit Account, Securities Account or Commodity Account.

“Commitment Percentage” means, as to any Lender, the percentage set forth opposite such
Lender’s name on Schedule 1, as amended from time to time.

“Commodity Account” means any “commodity account”, as defined in the Code, with such additions
to such term as may hereafter be made.

“Communication” has the meaning given it in Section 10.

“Compliance Certificate” means a certificate, duly executed by an authorized officer of
Borrower, appropriately completed and substantially in the form of Exhibit C.

“Contingent Obligation” means, for any Person, any direct or indirect liability, contingent or
not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation
of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted
or sold with recourse by that Person, or for which that Person is directly or indirectly liable;
(b) any obligations for undrawn letters of credit for the account of that Person; and (c) all
obligations from any interest rate, currency or commodity swap agreement, interest rate cap or
collar agreement, or other agreement or arrangement designated to protect a Person against
fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent
Obligation” does not include endorsements in the Ordinary Course of Business. The amount of a
Contingent Obligation is the stated or determined amount of the primary obligation for which the
Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability
for it determined by the Person in good faith; but the amount may not exceed the maximum of the
obligations under any guarantee or other support arrangement.

“Control Agreement” means any control agreement entered into among the depository institution
at which Borrower maintains a Deposit Account or the securities intermediary or commodity
intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and
Agent pursuant to which Agent obtains control (within the meaning of the Code) for the benefit of
the Lenders over such Deposit Account, Securities Account or Commodity Account.

“Credit Extension” means any Term Loan or any other extension of credit by Agent or the
Lenders for Borrower’s benefit.

“DEA” means the Drug Enforcement Administration of the United States of America, and any
successor agency thereof.

“Default” means any event which with notice or passage of time or both, would constitute an
Event of Default.

“Default Rate” has the meaning given it in Section 2.3(c).

“Deposit Account” means any “deposit account” as defined in the Code with such additions to
such term as may hereafter be made.

“Designated Deposit Account” means Borrower’s deposit account, account number 2000002596060,
maintained with Wells Fargo Bank, N.A. and over which Agent has been granted control for the
ratable benefit of all Lenders.

“Dollars,” “dollars” and “$” each means lawful money of the United States.

“Draw Period” means the period of time commencing upon the Closing Date and continuing through
the earliest to occur of (a) the Draw Period Termination Date, (b) an Event of Default, and (c) the
existence of any Default.

“Draw Period Termination Date” means December 31, 2011.

“Drug Application” means a new drug application, an abbreviated drug application, or a product
license application for any Product, as appropriate, as those terms are defined in the FDCA.

“Eligible Assignee” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund,
and (d) any other Person (other than a natural person) approved by Agent; provided, however, that
notwithstanding the foregoing, “Eligible Assignee” shall not include Borrower, any Guarantor or any
of Borrower’s or any Guarantor’s Affiliates or Subsidiaries. Notwithstanding the foregoing, in
connection with assignments by a Lender due to a forced divestiture at the request of any
regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall
mean any Person or party becoming an assignee incident to such forced divestiture.

“Equipment” means all “equipment”, as defined in the Code, with such additions to such term as
may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles
(including motor vehicles and trailers), and any interest in any of the foregoing.

“ERISA” means the Employee Retirement Income Security Act of 1974, and all regulations
promulgated thereunder.

“Event of Default” has the meaning given it in Section 8.

“Existing Subordinated Notes” means the 7.5556% Convertible Subordinated Notes due February 9,
2014, issued pursuant to that certain Indenture, dated February 9, 2009, providing for the issuance
of such notes, together with all other instruments and documents executed in connection therewith

“FDA” means the Food and Drug Administration of the United States of America, or any successor
entity thereto.

“FDCA” means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et
seq., and all regulations promulgated thereunder.

“Final Payment” means a payment (in addition to and not a substitution for the regular monthly
payments of principal plus accrued interest) due on the earlier to occur of (a) the Maturity Date,
(b) the acceleration of any Term Loan, and (c) the prepayment of a Term Loan pursuant to Section
2.2(c) or (d), equal to the Term Loan Commitments multiplied by the Final Payment Percentage.

“Final Payment Percentage” means three and one half of one percent (3.5%).

“Foreign Subsidiary” has the meaning given it in Exhibit A.

“Funding Date” means any date on which a Credit Extension is made to or on account of Borrower
which shall be a Business Day.

“GAAP” means generally accepted accounting principles set forth in the opinions and
pronouncements of the Accounting Principles Board of the American Institute of Certified Public
Accountants and statements and pronouncements of the Financial Accounting Standards Board or in
such other statements by such other Person as may be approved by a significant segment of the
accounting profession in the United States, which are applicable to the circumstances as of the
date of determination.

“General Intangibles” means all “general intangibles”, as defined in the Code, with such
additions to such term as may hereafter be made, and includes without limitation, all copyright
rights, copyright applications, copyright registrations and like protections in each work of
authorship and derivative work, whether published or unpublished, any patents, trademarks, service
marks and, to the extent permitted under applicable Law, any applications therefor, whether
registered or not, any trade secret rights, including any rights to unpatented inventions, payment
intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer
lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security
and other deposits, options to purchase or sell real or personal property, rights in all litigation
presently or hereafter pending (whether in contract, tort or otherwise), insurance policies
(including without limitation key man, property damage, and business interruption insurance),
payments of insurance and rights to payment of any kind.

“Governmental Approval” means any consent, authorization, approval, order, license, franchise,
permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or
other act by or in respect of, any Governmental Authority.

“Governmental Authority” means any nation or government, any state or other political
subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank
or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
functions of or pertaining to government, any securities exchange and any self-regulatory
organization.

“Guarantor” means any present or future guarantor of the Obligations.

“Indebtedness” means (a) indebtedness for borrowed money or the deferred price of property or
services, such as reimbursement and other obligations for surety bonds and letters of credit, (b)
obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease
obligations, and (d) Contingent Obligations.

“Indemnified Liabilities” has the meaning given it in Section 12.2.

“Indemnified Person” has the meaning given it in Section 12.2.

“Insolvency Proceeding” means any proceeding by or against any Person under the United States
Bankruptcy Code, or any other bankruptcy or insolvency Law, including assignments for the benefit
of creditors, compositions, extensions generally with its creditors, or proceedings seeking
reorganization, arrangement, or other relief.

“Intellectual Property” includes without limitation, all copyright rights, copyright
applications, copyright registrations and like protections in each work of authorship and
derivative work, whether published or unpublished, any patents, patent applications and like
protections, including improvements, divisions, continuations, renewals, reissues, extensions, and
continuations-in-part of the same, trademarks, trade names, service marks, mask works, rights of
use of any name, domain names, or any other similar rights, any applications therefor, whether
registered or not, and the goodwill of the business of Borrower connected with and symbolized
thereby, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights
to unpatented inventions, and any claims for damage by way of any past, present, or future
infringement of any of the foregoing.

“Interest Expense” means for any fiscal period with respect to Borrower and its Subsidiaries
on a consolidated basis, interest expense (whether cash or non-cash) determined in accordance with
GAAP for the relevant period ending on such date, including, in any event, interest expense with
respect to any Credit Extension and other Indebtedness of Borrower and its Subsidiaries, including,
without limitation or duplication, all commissions, discounts, or related amortization and other
fees and charges with respect to letters of credit and bankers’ acceptance financing and the net
costs associated with interest rate swap, cap, and similar arrangements, and the interest portion
of any deferred payment obligation (including leases of all types).

“Interest Period” means the one-month period starting on the first (1st) day of
each month and ending on the last day of such month; provided, however, that the first
(1st) Interest Period for each Term Loan shall commence on the date that the applicable
Term Loan is made and end on the last day of such month.

“Interest Rate Determination Date” means the second (2nd) Business Day prior to the
first (1st) day of the related Interest Period.

“Inventory” means all “inventory”, as defined in the Code, with such additions to such term as
may hereafter be made, and includes without limitation all merchandise, raw materials, parts,
supplies, packing and shipping materials, work in process and finished products, including without
limitation such inventory as is temporarily out of Borrower’s custody or possession or in transit
and including any returned goods and any documents of title representing any of the above.

“Investment” means any beneficial ownership interest in any Person (including stock,
partnership interest or other securities), and any loan, advance or capital contribution to any
Person.

“IP Agreement” means that certain Intellectual Property Security Agreement executed and
delivered by Borrower to Agent dated of even date herewith.

“Laws” means any and all federal, state, provincial, territorial, local and foreign statutes,
laws, judicial decisions, regulations, guidances, guidelines, ordinances, rules, judgments, orders,
decrees, codes, plans, injunctions, permits, concessions, grants, franchises, governmental
agreements and governmental restrictions, whether now or hereafter in effect, which are applicable
to any Borrower in any particular circumstance.

“Lender” means any one of the Lenders.

“Lenders” means the Persons identified on Schedule 1 hereto, and each assignee that becomes a
party to this Agreement pursuant to Section 12.1.

“Lenders’ Expenses” means all audit fees and expenses, costs, and expenses (including
reasonable attorneys’ fees and expenses) of Agent and Lenders for preparing, amending, negotiating,
administering, defending and enforcing the Loan Documents (including, without limitation, those
incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Agent or
the Lenders in connection with the Loan Documents.

“LIBOR Rate” means, for each Interest Period, the rate per annum determined by Agent (rounded
upwards, if necessary, to the next 1/100th%) by dividing (a) the Base LIBOR Rate for such Interest
Period, by (b) 100% minus the Reserve Percentage. The LIBOR Rate shall be adjusted on and as of
the effective day of any change in the Reserve Percentage.

“LIBOR Rate Margin” means eight percent (8.0%) per annum.

“Lien” means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or
other encumbrance of any kind, whether voluntarily incurred or arising by operation of Law or
otherwise against any property.

“Loan Documents” means, collectively, this Agreement, the Warrant, the Perfection Certificate,
the IP Agreement, any note, or notes or guaranties executed by Borrower or any Guarantor in
connection with the indebtedness governed by this Agreement, and any other present or future
agreement between Borrower and/or for the benefit of the Lenders and Agent in connection with this
Agreement, all as amended, restated, or otherwise modified.

“Loan Party” means Borrower and each Guarantor.

“Material Adverse Change” means (a) a material impairment in the perfection or priority of the
Agent’s Lien in the Collateral or in the value of such Collateral; (b) a material adverse change in
the business, operations, or condition (financial or otherwise) or prospects of Borrower that in
Agent’s credit judgment may impair the ability of Borrower to repay any of the Obligations; or (c)
a material impairment of the prospect of repayment of any portion of the Obligations.

“Material Intellectual Property” means all of Borrower’s Intellectual Property and license or
sublicense agreements or other agreements with respect to rights in Intellectual Property that are
material to the condition (financial or other), business or operations of Borrower as identified in
Schedule 5.2(d), as updated from time to time in accordance with Section 6.2(d), and if not so
identified in Schedule 5.2(d), as determined by Agent.

“Maturity Date” means May 27, 2014 for each Term Loan.

“Meda AB License Agreement” means the License and Supply Agreement, dated as of January 8,
2010, between EpiCept, EpiCept GmbH and Meda AB.

“Meda Licensed Products” means the “Product” as defined in the Meda AB License Agreement (as
in effect on the Closing Date).

“Meda Rights” means the rights to royalty or milestone payments under the Meda AB License
Agreement.

“Meda Royalty Deposit Account” means a deposit account of the Meda Royalty Subsidiary created
in connection with the Meda Royalty Monetization Transaction into which royalty or milestone
payments under the Meda AB License Agreement may be received; provided, however,
that until such time as the Meda Royalty Monetization Transaction has been consummated in
accordance with the conditions thereto, such Meda Royalty Deposit Account shall contain a zero
balance.

“Meda Royalty Monetization Transaction” means the contribution by EpiCept to the Meda Royalty
Subsidiary of the Meda Rights, the monetization by means of the contribution by EpiCept to the Meda
Royalty Subsidiary of the Meda Rights, the monetization by the Meda Royalty Subsidiary of such Meda
Rights and, solely if required pursuant to such transaction as a result of the termination of the
Meda AB License Agreement or the discontinuance of the royalty or milestone payments thereunder,
the transfer by EpiCept to the Meda Royalty Subsidiary of the Related Intellectual Property and
Related Contract Rights; provided, however, that such monetization transaction
shall be subject to the following conditions: (i) the transfer of the Meda Rights from EpiCept to
the Meda Royalty Subsidiary shall not take place until the consummation of such transaction and
until the other conditions to the Meda Royalty Monetization Transaction have been satisfied; (ii)
other than with respect to a non-recourse pledge of EpiCept’s membership interests in, or shares
of, a Meda Royalty Subsidiary, there shall be no recourse to any Borrower in connection with such
transaction; (iii) such transaction must have been approved in advance by the Board of Directors of
EpiCept; (iv) prior to or simultaneously with the consummation of such transaction, EpiCept shall
have received into a Collateral Account owned and in the name of EpiCept not less than six million
and no/100 dollars ($6,000,000) of net cash proceeds in connection therewith; and (v) in the event
that a reserve is established with respect to a portion of the monetized transaction proceeds, such
reserve shall be established with the Meda Royalty Subsidiary and used solely for the purpose of
making interest payments due in connection with such transaction.

“Meda Royalty Subsidiary” means Saw Mill Royalty Sub LLC, a Delaware limited liability
company, whose sole member is EpiCept, formed for the sole purpose of acquiring the Meda Rights,
and subsequently borrowing against or otherwise monetizing such rights or any other wholly owned
Subsidiary of EpiCept established solely for such purpose; provided, that; (i) there shall
only be one Meda Royalty Subsidiary in existence at any given time (except that if a replacement
Meda Royalty Subsidiary is formed, Borrower shall have 15 days from such formation to terminate the
existing Meda Royalty Subsidiary); (ii) prior to the consummation of the Meda Royalty Monetization
Transaction in accordance with the conditions thereto, such Subsidiary shall have no assets and
conduct no business other than that which is necessary to maintain its existence; (iii) other than
contribution of the Meda Rights upon consummation of the Meda Royalty Monetization Transaction, or
if required pursuant to the terms of the Meda Royalty Transaction as a result of termination of the
Meda AB License Agreement or the discontinuance of the royalty or milestone payments thereunder,
the transfer by EpiCept to the Meda Royalty Subsidiary of the Related Intellectual Property and
Related Contract Rights, no Borrower shall make any other contribution to the Meda Royalty
Subsidiary, and (iv) such Subsidiary shall be bankruptcy remote from EpiCept and the other
Borrowers.

“Obligations” means all of Borrower’s obligations to pay when due any debts, principal,
interest, Lenders’ Expenses, the Prepayment Fee, the Final Payment, and other amounts Borrower owes
the Lenders now or later, under this Agreement or the other Loan Documents, including, without
limitation, interest accruing after Insolvency Proceedings begin (whether or not allowed) and
debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Agent, and the
performance of Borrower’s duties under the Loan Documents.

“OFAC” means the U.S. Department of Treasury Office of Foreign Assets Control.

“OFAC Lists” means, collectively, the Specially Designated Nationals and Blocked Persons List
maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001)
and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the
rules and regulations of OFAC or pursuant to any other applicable Executive Orders.

“Operating Documents” means, for any Person, such Person’s formation documents, as certified
with the Secretary of State of such Person’s state of formation on a date that is no earlier than
30 days prior to the Closing Date, and (a) if such Person is a corporation, its bylaws in current
form, (b) if such Person is a limited liability company, its limited liability company agreement
(or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or
similar agreement), each of the foregoing with all current amendments or modifications thereto.

“Ordinary Course of Business” means, in respect of any transaction involving any Loan Party,
the ordinary course of business of such Loan Party, as conducted by such Loan Party in accordance
with past practices.

“Payment/Advance Form” means that certain form attached hereto as Exhibit B.

“Payment Date” means the first calendar day of each calendar month.

“Perfection Certificate” has the meaning given it in Section 5.1.

“Permits” means licenses, certificates, accreditations, product clearances or approvals,
provider numbers or provider authorizations, marketing authorizations, other authorizations,
registrations, permits, consents and approvals required in connection with the conduct of
Borrower’s or any Subsidiary’s business or to comply with any applicable Laws, including, without
limitation, drug listings and drug establishment registrations under 21 U.S.C. Section 510,
registrations issued by DEA under 21 U.S.C. Section 823 (if applicable to any Product), and those
issued by State governments for the conduct of Borrower’s or any Subsidiary’s business.

“Permitted Indebtedness” means:

(a) Borrower’s Indebtedness to the Lenders and Agent under this Agreement and the other Loan
Documents;

(b) Indebtedness existing on the Closing Date and described on Schedule 7.4;

(c) Subordinated Debt;

(d) unsecured Indebtedness to trade creditors incurred in the Ordinary Course of Business;

(e) Indebtedness secured by Permitted Liens; and

(f) extensions, refinancings, modifications, amendments and restatements of any items of
Permitted Indebtedness (a) through (e) above, provided, however, that the principal amount thereof
is not increased or the terms thereof are not modified to impose more burdensome terms upon
Borrower or its Subsidiary, as the case may be.

“Permitted Investments” means:

(a) Investments existing on the Closing Date and described on Schedule 7.7;

(b) Investments in EpiCept GmbH in an aggregate amount for any fiscal year not to exceed the
lesser of (i) $1,000,000 and (ii) the out-of-pocket costs and expenses of EpiCept GmbH plus ten
percent (10%) for such fiscal year, for the payment of such costs and expenses;

(c) Investments consisting of Cash Equivalents; and

(d) Investment in the Meda Royalty Subsidiary pursuant to the conditions set forth in the
definition of Meda Royalty Subsidiary.

“Permitted Liens” means:

(a) Liens existing on the Closing Date and shown on the Perfection Certificate or arising
under this Agreement and the other Loan Documents;

(b) Liens for taxes, fees, assessments or other government charges or levies, either not
delinquent or being contested in good faith and for which Borrower maintains adequate reserves on
its Books, provided, however, that no notice of any such Lien has been filed or recorded under the
Internal Revenue Code of 1986, as amended , and the Treasury Regulations adopted thereunder;

(c) purchase money Liens (i) on Equipment acquired or held by Borrower incurred for financing
the acquisition of the Equipment securing no more than One Hundred Thousand Dollars ($100,000) in
the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien
is confined to the property and improvements and the proceeds of the Equipment;

(d) statutory Liens securing claims or demands of materialmen, mechanics, carriers,
warehousemen, landlords and other Persons imposed without action of such parties, provided,
however, that they have no priority over any of Agent’s Lien and the aggregate amount of such Liens
does not any time exceed Twenty Five Thousand Dollars ($25,000);

(e) leases or subleases of real property granted in the Ordinary Course of Business, and
leases, subleases, non-exclusive licenses or sublicenses of property (other than real property or
Intellectual Property) granted in the Ordinary Course of Business, if the leases,
subleases, licenses and sublicenses do not prohibit granting Agent a security interest;

(f) banker’s liens, rights of setoff and Liens in favor of financial institutions incurred
made in the Ordinary Course of Business arising in connection with Borrower’s deposit accounts or
securities accounts held at such institutions to secure payment of fees and similar costs and
expenses subject to Borrower’s compliance with Section 6.6(b) hereof;

(g) Liens to secure payment of workers’ compensation, employment insurance, old-age pensions,
social security and other like obligations incurred in the Ordinary Course of Business (other than
Liens imposed by ERISA);

(h) Liens arising from judgments, decrees or attachments in circumstances not constituting an
Event of Default under Section 8.5 or 8.7;

(i) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in
title and similar charges or encumbrances affecting real property not constituting a Material
Adverse Change;

(j) non-exclusive licenses of Intellectual Property granted to third parties in the Ordinary
Course of Business;

(k) Liens incurred in the extension, renewal or refinancing of the indebtedness secured by
Liens described in (a) and (c) above, but any extension, renewal or replacement Lien must
be limited to the property encumbered by the existing Lien and the principal amount of the
Indebtedness may not increase; and

(l) in connection with the Meda Royalty Monetization Transaction, a non-recourse pledge of
EpiCept’s membership interests in, or shares of, a Meda Royalty Subsidiary to the lender(s) or
other participant(s) in the Meda Royalty Monetization Transaction.

“Person” means any individual, sole proprietorship, partnership, limited liability company,
joint venture, company, trust, unincorporated organization, association, corporation, institution,
public benefit corporation, firm, joint stock company, estate, entity or government agency.

“Prepayment Fee” means with respect to any Term Loan subject to prepayment prior to the
Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, an
additional fee payable to the Lenders in amount equal to:

(a) for a prepayment made on or after the Closing Date through and including the date which is
twelve (12) months after the Closing Date, six percent (6.0%) multiplied by the original Term Loan
Commitments;

(b) for a prepayment made after the date which is twelve (12) months after the Closing Date
through and including the date which is twenty-four (24) months after the Closing Date, four
percent (4.0%) multiplied by the original Term Loan Commitments; and

(c) for a prepayment made after the date which is twenty-four (24) months after the Closing
Date and prior to the Maturity Date, two percent (2.0%) multiplied by the original Term Loan
Commitments.

“Pro Rata Share” means, as determined by Agent, with respect to each Lender, a percentage
(expressed as a decimal, rounded to the ninth decimal place) determined by dividing the amount of
Term Loans held by such Lender by the aggregate amount of all outstanding Term Loans.

“Products” means any products manufactured, sold, developed, tested or marketed by any
Borrower or any of its Subsidiaries, including without limitation, those products set forth on
Schedule 5.11 (as updated from time to time in accordance with Section 6.2(d) above); provided,
however, that if Borrower shall fail to comply with the obligations under Section 6.2(d) to give
notice to Agent and update Schedule 5.11 prior to manufacturing, selling, developing, testing or
marketing any new Product, any such improperly undisclosed Product shall be deemed to be included
in this definition; and provided, further, that products manufactured by Borrower for unaffiliated
third parties shall not be deemed “Products” hereunder.

“Qualifying Transaction” means (i) an equity contribution including, but not limited to,
preferred stock; (ii) convertible debt in form and substance, and on terms satisfactory to Agent,
which is subordinated to the Obligations in a manner satisfactory to Agent and which has a maturity
no earlier than 366 days after the Maturity Date; (iii) drug development partnership; or (iv)
royalty financing including, but not limited to, a Meda Royalty Monetization Transaction, in all
cases, without any obligation to repay such net cash proceeds and in form and substance reasonably
satisfactory to Agent.

“Registered Organization” means any “registered organization” as defined in the Code, with
such additions to such term as may hereafter be made.

“Related Intellectual Property and Related Contract Rights” means (i) the “EpiCept
Technology,” as defined in the Meda AB License Agreement (as in effect on the date hereof), owned
by EpiCept and licensed to Meda AB as of the Closing Date pursuant to the Meda AB License
Agreement, and (ii) any agreements with respect to the manufacture, packaging and labeling of the
Meda Licensed Products.

“Required Lenders” means Lenders having (a) more than 60% of the Term Loan Commitments of all
Lenders, or (b) if such Term Loan Commitments have expired or been terminated, more than 60% of the
aggregate outstanding principal amount of the Term Loans; provided, however, that so long as a
party that is a Lender hereunder on the Closing Date does not assign any portion of its Term Loan
Commitment or Term Loan, the term “Required Lenders” shall include such Lender. For purposes of
this definition only, a Lender shall be deemed to include itself, and any Lender that is an
Affiliate or Approved Fund of such Lender.

“Required Permit” means a Permit (a) issued or required under Laws applicable to the business
of Borrower or any of its Subsidiaries or necessary in the manufacturing, importing, exporting,
possession, ownership, warehousing, marketing, promoting, sale, labeling, furnishing, distribution
or delivery of goods or services under Laws applicable to the business of Borrower or any of its
Subsidiaries or any Drug Application (including without limitation, at any point in time, all
licenses, approvals and permits issued by the FDA or any other applicable Governmental Authority
necessary for the testing, manufacture, marketing or sale of any Product by any applicable
Borrower(s) as such activities are being conducted by such Borrower with respect to such Product at
such time), and (b) issued by any Person from which Borrower or any of their Subsidiaries have
received an accreditation.

“Requirement of Law” means as to any Person, the organizational or governing documents of such
Person, and any Law (statutory or common), treaty, rule or regulation or determination of an
arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon
such Person or any of its property or to which such Person or any of its property is subject.

“Reserve Percentage” means, on any day, for any Lender, the maximum percentage prescribed by
the Board of Governors of the Federal Reserve System (or any successor Governmental Authority) for
determining the reserve requirements (including any basic, supplemental, marginal, or emergency
reserves) that are in effect on such date with respect to eurocurrency funding (currently referred
to as “eurocurrency liabilities”) of that Lender, but so long as such Lender is not required or
directed under applicable regulations to maintain such reserves, the Reserve Percentage shall be
zero.

“Responsible Officer” means any of the President and Chief Executive Officer or Chief
Financial Officer of Borrower.

“Secured Promissory Note” has the meaning given it in Section 2.7.

“Secured Promissory Note Record” means a record maintained by each Lender with respect to the
outstanding Obligations and credits made thereto.

“Securities Account” means any “securities account”, as defined in the Code, with such
additions to such term as may hereafter be made.

“Subordinated Debt” means indebtedness incurred by Borrower subordinated to all of Borrower’s
now or hereafter indebtedness to the Lenders (pursuant to a subordination, intercreditor, or other
similar agreement in form and substance satisfactory to Agent and the Lenders entered into between
Agent, Borrower and the other creditor), on terms acceptable to Agent and the Lenders.

“Subsidiary” means, with respect to any Person, any Person of which more than 50.0% of the
voting stock or other equity interests (in the case of Persons other than corporations) is owned or
controlled, directly or indirectly, by such Person or one or more of Affiliates of such Person.

“Term Loan” or “Term Loans” has the meaning given it in Section 2.2(a).

“Term Loan Commitment” means, for any Lender, the obligation of such Lender to make a Term
Loan, up to the principal amount shown on Schedule 1. “Term Loan Commitments” means the aggregate
amount of such commitments of all Lenders.

“Tranche One Exercise Price” means the closing price of the Borrower’s common stock on the
date immediately prior to the Closing Date.

“Tranche Two Eligibility Date” means the date on which Agent determines that Borrower has
satisfied each of the following conditions precedent to an advance in respect of Tranche Two: (a)
Borrower has provided a deposit in accordance with a contract with a clinical research organization
with experience in the indications covered by Borrower’s drug candidates for conducting Phase III
clinical studies of either (i) Ceplene, or (ii) AmiKet (formerly known as EpiCept NP-1); and (b)
prior to December 31, 2011, Borrower has raised net cash proceeds of at least five million and
no/100 dollars ($5,000,000.00) pursuant to a Qualifying Transaction.

“Tranche Two Exercise Price” means the closing price of the Borrower’s common stock on the
date immediately prior to the date Tranche Two is advanced, if any.

“Transfer” has the meaning given it in Section 7.1.

“Warrants” means those certain Warrants evidencing each Lender’s or such Lender’s Affiliates’
right to acquire its respective Pro Rata Share of (i) up to that number of shares of Borrower’s
common stock equal to 8% of (A) Tranche One divided by (B) the Tranche One Exercise Price, at an
exercise price equal to the Tranche One Exercise Price, dated as of the Closing Date and executed
by Borrower in favor of each Lender or such Lender’s Affiliates, and (ii) up to that number of
shares of Borrower’s common stock equal to 8% of (X) the amount of Tranche Two divided by (Y) the
Tranche Two Exercise Price, at an exercise price equal to the Tranche Two Exercise Price, dated as
of the date Tranche Two is advanced and executed by Borrower in favor of each Lender or such
Lender’s Affiliates.

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)]IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be executed as of the Closing Date.

BORROWER:

EPICEPT CORPORATION

By:      

Name:      

Title:      

MAXIM PHARMACEUTICALS INC.

By:      

Name:      

Title:      

CYTOVIA, INC.

By:      

Name:      

Title:      

AGENT:

MIDCAP FUNDING III, LLC,

as Agent for Lenders

By:      

Name:      

Title:      

LENDERS:

MIDCAP FUNDING III, LLC,

as a Lender

By:      

Name:      

Title:      

1

EXHIBITS AND SCHEDULES

	 	 	 
	EXHIBITS 	 	 
	Exhibit A

Exhibit B

Exhibit C

Exhibit D

Exhibit E

	 	Collateral

Loan Payment / Advance Request Form

Compliance Certificate

Secured Promissory Note

Form of Warrant
	SCHEDULES

	 	

	 

	 	

	Schedule 1

Schedule 5.1

Schedule 5.2

Schedule 5.3

Schedule 5.11

Schedule 6.12

Schedule 7.4

Schedule 7.7

	 	Lenders and Commitments

Organizational Information

Collateral Disclosures

Litigation

Products and Required Permits

Post Closing Obligations

Indebtedness

Investments

2

EXHIBIT A

COLLATERAL

The Collateral consists of all assets of Borrower, including all of Borrower’s right, title
and interest in and to the following personal property:

(a) all goods, Accounts (including health-care insurance receivables), Equipment, Inventory,
contract rights or rights to payment of money, leases, license agreements, franchise agreements,
General Intangibles, commercial tort claims, documents, instruments (including any promissory
notes), chattel paper (whether tangible or electronic), cash, deposit accounts, investment
accounts, commodity accounts and other Collateral Accounts, all certificates of deposit, fixtures,
letters of credit rights (whether or not the letter of credit is evidenced by a writing),
securities, and all other investment property, supporting obligations, and financial assets,
whether now owned or hereafter acquired, wherever located; and

(b) all Borrower’s Books relating to the foregoing, and any and all claims, rights and
interests in any of the above and all substitutions for, additions, attachments, accessories,
accessions and improvements to and replacements, products, proceeds and insurance proceeds of any
or all of the foregoing.

Notwithstanding the foregoing, the Collateral shall not include any rights of the Borrower
under the Meda AB License Agreement, but prior to the consummation of the Meda Royalty Monetization
Transaction, shall include the Meda License Proceeds. The term “Meda License Proceeds” means,
collectively, all cash, Accounts, license and royalty fees, claims, products, awards, judgments,
insurance claims, and other revenues, proceeds or income, arising out of, derived from or relating
to the Meda AB License Agreement, and any claims for damage by way of any past, present or future
infringement of the Meda AB License Agreement (including, without limitation, all cash, royalty
fees, other proceeds, Accounts and General Intangibles that consist of rights of payment to or on
behalf of a Loan Party and the proceeds from the sale, licensing or other disposition of all or any
part of, or rights in, the Meda AB License Agreement by or on behalf of a Loan Party.

Agent and Lenders further acknowledge that the Collateral shall not include more than 65% of
the voting securities of any Subsidiary that is not organized under the laws of the United States
or any of its states (each a “Foreign Subsidiary”) if such pledge would cause a material increase
in the Borrower’s federal income tax liability.

Pursuant to the terms of a certain negative pledge arrangement with Agent and Lenders,
Borrower has agreed not to encumber any of its rights under the Meda AB License Agreement;
provided, however, Borrower may enter into the Meda Royalty Monetization
Transaction, so long as its Board of Directors has approved such transaction.

3

EXHIBIT B

LOAN PAYMENT/ADVANCE REQUEST FORM

Deadline is Noon E.S.T.

Date:       , 201      

LOAN PAYMENT:

	 	 	 
	From Account #      

(Deposit Account #)

	 	To Account #     

(Loan Account #)

Principal $      and/or Interest
$     

	 	 	 	 	 
	Authorized Signature:

	 	Phone Number:
	 	     
	
 
	 	 	 	 
	Print Name/Title:

	 	

	 	

	 

	 	

	 	

Loan Advance:

Complete Outgoing Wire Request section below if all or a portion of the funds from this loan
advance are for an outgoing wire.

	 	 	 
	From Account #      

(Loan Account #)

	 	To Account #     

(Deposit Account #)

Amount of Advance $     

All Borrower’s representations and warranties in the Loan and Security Agreement are true,
correct and complete in all material respects on the

date of the request for an advance; provided, however, that such materiality qualifier shall
not be applicable to any representations and warranties

that already are qualified or modified by materiality in the text thereof; and provided,
further, that those representations and warranties expressly

referring to a specific date shall be true, accurate and complete in all material respects as
of such date:

	 	 	 	 	 
	Authorized Signature:

	 	Phone Number:
	 	     
	
 
	 	 	 	 
	Print Name/Title:

	 	

	 	

	 

	 	

	 	

Outgoing Wire Request:

Complete only if all or a portion of funds from the loan advance above is to be wired.

	 	 	 	 	 
	Beneficiary Name:       

Beneficiary Lender:       

	 	 	 	Amount of Wire: $

Account Number:
	
 
	 	 	 	 
	City and State:

	 	

	 	

	 

	 	

	 	

	Beneficiary Lender Transit (ABA) #:

	 	Beneficiary Lender Code (Swift, Sort, Chip, etc.):
	 	

	 

	 	

	 	

	(For International Wire Only)

	 	

	 	

	Intermediary Lender:

	 	Transit (ABA) #:
	 	

	 

	 	 
	 	

	For Further Credit to:

	 	

	 	

	 

	 	 
	 	

	Special Instruction:

	 	

	 	

	 

	 	 
	 	

By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be
processed in accordance with and subject to the

terms and conditions set forth in the agreements(s) covering funds transfer service(s), which
agreements(s) were previously received and

executed by me.

	 	 	 
	Authorized Signature:       

Print Name/Title:       

	 	2nd Signature (if required):      

Print Name/Title:      

Telephone #: Telephone #: ______EXHIBIT C

COMPLIANCE CERTIFICATE

	 	 	 
	TO:

FROM:

DATE:

	 	MidCap Funding III, LLC, as Agent

     

     , 201     

The undersigned authorized officer of       
(“Borrower”) certifies that under the terms and conditions of the Loan and Security Agreement
between Borrower, Agent and the Lenders (the “Agreement”):

(1) Borrower is in complete compliance with all required covenants for the month ending
     , 201      , except as noted below;

(2) there are no Events of Default;

(3)  all representations and warranties in the Agreement are true and correct in all material
respects on this date except as noted below; provided, however, that such materiality qualifier
shall not be applicable to any representations and warranties that already are qualified or
modified by materiality in the text thereof; and provided, further, that those representations and
warranties expressly referring to a specific date shall be true, accurate and complete in all
material respects as of such date;

(4) Borrower, and each of its Subsidiaries, has timely filed all required tax returns and
reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments,
deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of
Section 5.8 of the Agreement; and

(5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries
relating to unpaid employee payroll or benefits of which Borrower has not previously provided
written notification to Agent.

Attached are the required documents supporting the certifications set forth in this Compliance
Certificate. The undersigned certifies, in his/her capacity as an officer of the Borrower, that
these are prepared in accordance with GAAP consistently applied from one period to the next except
as explained in an accompanying letter or footnotes. The undersigned acknowledges, in his/her
capacity as an officer of Borrower, that no borrowings may be requested at any time or date of
determination that Borrower is not in compliance with any of the terms of the Agreement, and that
compliance is determined not just at the date this certificate is delivered. Capitalized terms
used but not otherwise defined herein shall have the meanings given them in the Agreement.

	 	 	 	 	 
	Please indicate compliance status by circling Yes/No under “Complies” column.
	 

	Reporting Covenant

	 	Required
	 	Complies
	 

	 	 
	 	 
	Monthly Financial Statements

	 	Monthly within 30 days
	 	Yes No
	
 
	 	 
	 	 
	Audited Financial Statements

	 	Annually within 120 days after FYE
	 	Yes No
	 

	 	 
	 	

	Board Approved Projections

	 	Annually within 30 days after FYE
	 	Yes No
	 

	 	 
	 	

	Compliance Certificate

	 	Monthly within 30 days
	 	Yes No
	 

	 	 
	 	

4

The following are the exceptions with respect to the certification above: (If no exceptions
exist, state “No exceptions to note.”)

—
—
—
—
—

	 	 	 
	EPICEPT CORPORATION	 	AGENT USE ONLY
	By:

Name:

Title:
	 	Received by:      

authorized signer

Date:      

Verified:      

authorized signer

Date:      

Compliance Status: Yes No

SCHEDULE 1

LENDERS AND COMMITMENTS

	 	 	 	 	 	 	 	 	 
	Lender	 	Term Loan Commitment	 	Commitment Percentage
	MidCap Funding III, LLC

	 	$	10,600,000	 	 		100	%
	 

	 	 	 	 	 	 	 	 
	TOTAL

	 	$	10,600,000	 	 	 	100	%
	 

	 	 	 	 	 	 	 	 

5

SCHEDULE 5.1

ORGANIZATIONAL INFORMATION

Legal Name of Borrower:

Type of Legal Entity:

State of Organization:

Organizational Identification Number:

Tax Identification Number:

Principal Place of Business:

6

SCHEDULE 5.2

COLLATERAL DISCLOSURES

Schedule 5.2(a) – Collateral Accounts:

Schedule 5.2(d) – Intellectual Property:

Schedule 5.2(e) – Location of Collateral:

SCHEDULE 5.3

LITIGATION

7

SCHEDULE 5.11

PRODUCTS AND REQUIRED PERMITS

8

SCHEDULE 6.12

POST CLOSING OBLIGATIONS

Borrowers shall satisfy and complete each of the following obligations, or provide Agent each
of the items listed below, as applicable, on or before the date indicated below, all to the
satisfaction of Agent in its sole and absolute discretion:

	1.	 	By not later than June 27, 2011, deliver to Agent original stock certificates and
accompanying stock powers of Maxim Pharmaceuticals Inc. and Cytovia, Inc. equal to 100% of the
outstanding equity interests of such entities.

	2.	 	By not later than June 27, 2011, deliver to Agent Control Agreements with respect to the
Deposit and Securities Accounts located at Wells Fargo Bank, N.A. and Silicon Valley Bank;

	3.	 	By not later than June 27, 2011, deliver to Agent, evidence satisfactory to Agent that
EpiCept’s Securities Account at Bear Stearns be closed and all funds on deposit therein be
transferred to a Deposit Account subject to (or required to be subject to pursuant to
paragraph 1 of this Schedule 6.12) a Control Agreement;

	4.	 	By not later than June 27, 2011, deliver to Agent a landlord’s consent executed in favor of
Agent in respect of Borrower’s facilities at 777 Old Saw Mill River Road, Tarrytown, NY 10591;

	5.	 	By not later than June 3, 2011, deliver to Agent evidence satisfactory to Agent that EpiCept
has repaid in full the outstanding loans and other obligations under the Existing Subordinated
Notes; and

	6.	 	By not later than June 27, 2011, execute and deliver to Agent all documentation required by
Agent to pledge to Agent 65% of the outstanding equity interests of EpiCept GmbH.

Borrower’s failure to complete and satisfy any of the above obligations on or before the date
indicated above, or Borrower’s failure to deliver any of the above listed items on or before the
date indicated above, shall constitute an immediate an automatic Event of Default.

9

SCHEDULE 7.4

INDEBTEDNESS AS OF THE CLOSING DATE

10

SCHEDULE 7.7

INVESTMENTS AS OF THE CLOSING DATE

11EX-10.2

W11D-01

THIS COMMON STOCK PURCHASE WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) NOR QUALIFIED UNDER
SECURITIES LAWS OF ANY STATE, AND MAY NOT BE SOLD OR OFFERED FOR SALE UNLESS A REGISTRATION
STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE LAW, OR SUCH
SALE IS PERMITTED UNDER RULE 144 OF THE ACT OR OTHERWISE EXEMPT FROM THE REGISTRATION AND
PROSPECTUS DELIVERY REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE LAW. THIS COMMON STOCK
PURCHASE WARRANT HAS BEEN ACQUIRED, AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF
WILL BE ACQUIRED, FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO THE DISTRIBUTION THEREOF.

COMMON STOCK PURCHASE WARRANT

EPICEPT CORPORATION

Warrant Shares: 1,092,063 Issue Date: May 27, 2011

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received,
MidCap Financial, LLC, a Delaware limited liability company, or its assigns (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Issue Date and on or prior to the close of
business on May 27, 2016 (the “Termination Date”) but not thereafter, to subscribe for and
purchase from EpiCept Corporation, a Delaware corporation (the “Company”), up to 1,092,063
shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock, par
value $0.0001 per share, of the Company (the “Common Stock”). The purchase price of one
share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).

Section 1. Definitions. Capitalized terms used and not otherwise defined
herein shall have the meanings set forth in that certain Loan and Security Agreement (the “Loan
Agreement”), dated May 27, 2011, among the Company, MidCap Funding III, LLC, a Delaware limited
liability company, as the Agent thereunder, the Lenders and other parties thereto.

Section 2. Exercise.

a) Exercise of the purchase rights represented by this Warrant may be made, in whole or
in part, at any time or times on or after the Issue Date and on or before the Termination
Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder
appearing on the books of the Company) of a duly executed facsimile or electronic (pdf) copy
of the Notice of Exercise Form annexed hereto (or by delivery of an original or copy of such
Notice of Exercise Form by any other method permitted for providing notices under the Loan
Agreement). Within three (3) Trading Days (as used herein, “Trading Day” means a day
on which the principal Trading Market is open for trading, and “Trading Market”
means any of the following markets or exchanges on which the Common Stock is listed or
quoted for trading on the date in question: the NYSE AMEX, the Nasdaq Capital Market, the
Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the
OTC Bulletin Board (or any successors to any of the foregoing)) following the date of
exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares
specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on
a United States bank unless the cashless exercise procedure specified in Section 2(c) below
is specified in the applicable Notice of Exercise. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the
Company until the Holder has purchased all of the Warrant Shares available hereunder and the
Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in
purchases of a portion of the total number of Warrant Shares available hereunder shall have
the effect of reducing the outstanding number of Warrant Shares purchasable hereunder by an
amount equal to the applicable number of Warrant Shares purchased. In the event of any
dispute or discrepancy, the records of the Holder shall be controlling and determinative in
the absence of manifest error. The Company shall maintain records showing the number of
Warrant Shares purchased and the date of such purchases. The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this
paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number
of Warrant Shares available for purchase hereunder at any given time may be less than the
amount stated on the face hereof.

b) Exercise Price. The exercise price per share of the Common Stock under this
Warrant shall be $0.63, subject to adjustment hereunder (the “Exercise Price”).

c) Cashless Exercise. At the option of the Holder, this Warrant may be
exercised, in whole or in part, at any time that this Warrant shall be exercisable and the
VWAP shall exceed the Exercise Price, by means of a “cashless exercise” in which the Holder
shall be entitled, without any obligation to pay the Exercise Price in cash, to receive a
certificate for the number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:

	 	(A)	 	= the VWAP on the Trading Day immediately preceding the date
on which Holder elects to exercise this Warrant by means of a “cashless
exercise,” as set forth in the applicable Notice of Exercise;

	 	(B)	 	= the Exercise Price of this Warrant, as adjusted hereunder;
and

	 	(X)	 	= the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.

“VWAP” means, for any date, the price determined by the first of the following
clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market,
the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as
reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to
4:02 p.m. (New York City time)), (b)  if the National Association of Securities Dealers,
Inc. OTC Bulletin Board (the “OTC Bulletin Board”) is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for
trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in
the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the
Common Stock so reported, or (d) in all other cases, the fair market value of a share of
Common Stock as determined by an independent appraiser selected in good faith by the Holder
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by
the Company.

Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant
shall, to the extent not previously exercised, be automatically exercised via cashless
exercise pursuant to this Section 2(c).

d) Mechanics of Exercise.

i. Delivery of Certificates Upon Exercise. Certificates for
            shares purchased hereunder shall, subject to Section 4(d) below, be
transmitted by the Transfer Agent to the Holder by crediting the account of
the Holder’s prime broker with The Depository Trust Company through its
Deposit or Withdrawal at Custodian system (“DWAC”), if the Company
is then a participant in such system, and either (A) there is an effective
registration statement permitting the issuance of the Warrant Shares to and
resale of the Warrant Shares by Holder (or the Warrant Shares may be resold
pursuant to SEC Rule 144) or (B) this Warrant is being exercised via
cashless exercise, and otherwise by physical delivery to the address
specified by the Holder in the Notice of Exercise by the date that is three
(3) Trading Days after the latest of (A) the delivery to the Company of the
Notice of Exercise and (B) payment of the aggregate Exercise Price as set
forth above (including by cashless exercise) (such date, the “Warrant
Share Delivery Date”). The Warrant Shares shall be deemed to have been
issued, and Holder or any other person so designated to be named therein
shall be deemed to have become a holder of record of such shares for all
purposes, as of the date the Warrant has been exercised, with payment to the
Company of the Exercise Price (or by cashless exercise) and all taxes
required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid. If the Company fails
for any reason to deliver to the Holder certificates evidencing the Warrant
Shares subject to a Notice of Exercise by the Warrant Share Delivery Date,
the Company shall pay to the Holder, in cash, as liquidated damages and not
as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $2 per Trading Day (increasing to $4 per Trading Day on the
fifth Trading Day after such liquidated damages begin to accrue) for each
Trading Day after such Warrant Share Delivery Date until such certificates
are delivered or Holder rescinds such exercise.

ii. Delivery of New Warrants Upon Exercise. If this Warrant
shall have been exercised in part, the Company shall, at the request of a
Holder and upon surrender of this Warrant certificate, at the time of
delivery of the certificate or certificates representing Warrant Shares,
deliver to the Holder a new Warrant evidencing the rights of the Holder to
purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.

iii. Rescission Rights. If the Company fails to cause the
Transfer Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant
Share Delivery Date, then the Holder will have the right to rescind such
exercise.

iv. Compensation for Buy-In on Failure to Timely Deliver
Certificates Upon Exercise; Remedies Cumulative. In addition to any
other rights available to the Holder, if the Company fails to cause the
Transfer Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to an exercise on or before the
Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or
the Holder’s brokerage firm otherwise purchases, shares of Common Stock to
deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by
which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y)
the amount obtained by multiplying (1) the number of Warrant Shares that the
Company was required to deliver to the Holder in connection with the
exercise at issue times (2) the price at which the sell order giving rise to
such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of Warrant
Shares for which such exercise was not honored (in which case such exercise
shall be deemed rescinded) or deliver to the Holder the number of shares of
Common Stock that would have been issued had the Company timely complied
with its exercise and delivery obligations hereunder. The Holder shall
provide the Company written notice indicating the amounts payable to the
Holder in respect of the Buy-In and, upon request of the Company, evidence
of the amount payable by the Company to the Holder hereunder. No provision
of this Warrant, including without limitation any right of the Holder to any
payment or liquidated damages, rescission or any other remedy provided for
in this Warrant, shall limit a Holder’s right to pursue any other remedies
available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with
respect to the Company’s failure to timely deliver certificates representing
            shares of Common Stock upon exercise of the Warrant as required pursuant to
the terms hereof.

v. No Fractional Shares or Scrip. No fractional shares or
scrip representing fractional shares shall be issued upon the exercise of
this Warrant. As to any fraction of a share which the Holder would
otherwise be entitled to purchase upon such exercise, the Company shall, at
its election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.

vi. Charges, Taxes and Expenses. Issuance of certificates for
Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such
certificate, all of which taxes and expenses shall be paid by the Company,
and such certificates shall be issued in the name of the Holder or in such
name or names as may be directed by the Holder; provided,
however, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form
attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any
transfer tax incidental thereto.

vii. Closing of Books. The Company will not close its
stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

Section 3. Certain Adjustments.

a) Stock Dividends and Splits. If the Company, at any time while this Warrant
is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in
            shares of Common Stock (which, for avoidance of doubt, shall not include any shares of
Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of
            shares, or (iv) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding
treasury shares, if any) outstanding immediately before such event and of which the
denominator shall be the number of shares of Common Stock outstanding immediately after such
event, and the number of shares issuable upon exercise of this Warrant shall be
proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain
unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to
Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock
Equivalents or rights to purchase stock, warrants, securities or other property pro rata to
the record holders of any class of shares of Common Stock (the “Purchase Rights”),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase
Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
immediately before the date on which a record is taken for the grant, issuance or sale of
such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights.

c) Pro Rata Distributions. If the Company, at any time while this Warrant is
outstanding, shall distribute to all holders of Common Stock (and not to the Holder)
evidences of its indebtedness or assets (including cash and cash dividends) or rights or
warrants to subscribe for or purchase any security, then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the
record date fixed for determination of stockholders entitled to receive such distribution by
a fraction of which the denominator shall be the VWAP determined as of the record date
mentioned above, and of which the numerator shall be such VWAP on such record date less the
then per share fair market value at such record date of the portion of such assets or
evidence of indebtedness so distributed applicable to one outstanding share of the Common
Stock as determined by the Board of Directors in good faith. In either case the adjustments
shall be described in a statement provided to the Holder of the portion of assets or
evidences of indebtedness so distributed or such subscription rights applicable to one share
of Common Stock. Such adjustment shall be made whenever any such distribution is made and
shall become effective immediately after the record date mentioned above.

d) Fundamental Transaction. If, at any time while this Warrant is outstanding,
(i) the Company, directly or indirectly, in one or more related transactions effects any
merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or
property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into
or exchanged for other securities, cash or property, (v) the Company, directly or
indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons
whereby such other Person or group acquires more than 50% of the outstanding shares of
Common Stock (not including any shares of Common Stock held by the other Person or other
Persons making or party to, or associated or affiliated with the other Persons making or
party to, such stock or share purchase agreement or other business combination) or (vi) any
“person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the
Exchange Act) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under the
Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power
represented by issued and outstanding Common Shares (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have
the right to receive, for each Warrant Share that would have been issuable upon such
exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder, the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the “Alternate Consideration”) receivable as a result of such
Fundamental Transaction by a holder (assuming such holder sold, exchanged or otherwise
transferred such shares in connection with such Fundamental Transaction) of the number of
            shares of Common Stock for which this Warrant is exercisable immediately prior to such
Fundamental Transaction. For purposes of any such exercise, the Exercise Price shall be
appropriately apportioned to apply to such Alternate Consideration based on the amount of
Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different
components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the
Holder shall be given the same choice as to the Alternate Consideration it receives upon any
exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything
to the contrary, in the event of a Fundamental Transaction that is (1) an all cash
transaction, (2) a “Rule 13e-3 transaction” as defined in Rule 13e-3 under the Exchange Act,
or (3) a Fundamental Transaction involving a person or entity not traded on a national
securities exchange, including, but not limited to, the Nasdaq Global Select Market, the
Nasdaq Global Market, or the Nasdaq Capital Market, the Company or any Successor Entity (as
defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or
within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant
from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value
of the remaining unexercised portion of this Warrant on the date of the consummation of such
Fundamental Transaction. “Black Scholes Value” means the value of this Warrant
based on the Black and Scholes Option Pricing Model obtained from the “OV” function on
Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation of the
applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day
volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately
following the public announcement of the applicable Fundamental Transaction, (C) the
underlying price per share used in such calculation shall be the sum of the price per share
being offered in cash, if any, plus the value of any non-cash consideration, if any, being
offered in such Fundamental Transaction and (D) a remaining option time equal to the time
between the date of the public announcement of the applicable Fundamental Transaction and
the Termination Date. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor or acquirer (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant
in accordance with the provisions of this Section 3(c) pursuant to written agreements in
form and substance reasonably satisfactory to the Holder and approved by the Holder (without
unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the
Holder, deliver to the Holder in exchange for this Warrant a security of the Successor
Entity evidenced by a written instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the
exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price
which applies the exercise price hereunder to such shares of capital stock (but taking into
account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this
Warrant immediately prior to the consummation of such Fundamental Transaction), and which is
reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such
Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant
referring to the “Company” shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company
under this Warrant with the same effect as if such Successor Entity had been named as the
Company herein.

e) Calculations. All calculations under this Section 3 shall be made to the
nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this
Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a
given date shall be the sum of the number of shares of Common Stock (excluding treasury
            shares, if any) issued and outstanding.

f) Notice to Holder.

i. Adjustment to Exercise Price. Whenever the Exercise Price is
adjusted pursuant to any provision of this Section 3, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after
such adjustment and any resulting adjustment to the number of Warrant Shares
and setting forth a brief statement of the facts requiring such adjustment.

ii. Notice to Allow Exercise by Holder. If (A) the Company
shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash
dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants
to subscribe for or purchase any shares of capital stock of any class or of
any rights, (D) the approval of any stockholders of the Company shall be
required in connection with any reclassification of the Common Stock, any
consolidation or merger to which the Company is a party, any sale or
transfer of all or substantially all of the assets of the Company, or any
compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Company, then, in each case, the Company shall cause to be
mailed to the Holder at its last address as it shall appear upon the Warrant
Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the
date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be
taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are
to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to
become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their
            shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to mail such notice or
any defect therein or in the mailing thereof shall not affect the validity
of the corporate action required to be specified in such notice. To the
extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any of the
Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such
notice, except as may otherwise be expressly set forth herein.

Section 4. Transfer of Warrant.

a) Transferability. This Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender
of this Warrant at the principal office of the Company or its designated agent, together
with a written assignment of this Warrant substantially in the form attached hereto duly
executed by the Holder or its agent or attorney and funds sufficient to pay any transfer
taxes payable upon the making of such transfer. Upon such surrender and, if required, such
payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in
such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the
portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The
Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.

b) New Warrants. This Warrant may be divided or combined with other Warrants
upon presentation hereof at the aforesaid office of the Company, together with a written
notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any
transfer which may be involved in such division or combination, the Company shall execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges
shall be dated the initial issuance date of this Warrant and shall be identical with this
Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c) Warrant Register. The Company shall register this Warrant, upon records to
be maintained by the Company for that purpose (the “Warrant Register”), in the name
of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any
exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.

d) Exchange Act Reports; Legend. 

(i) With a view to making available to the Holder the benefits of Securities and
Exchange Commission (“SEC”) Rule 144 and any other rule or regulation of the SEC
that may at any time permit the Holder to sell securities of the Company to the public
without registration or pursuant to a registration on Form S-3, the Company shall, so long
as it is subject to the reporting requirements of the Securities Act of 1933 (as amended,
and the rules and regulations promulgated thereunder, the “Securities Act”) and the
Securities Exchange Act of 1934 (as amended, and the rules and regulations promulgated
thereunder, the “Exchange Act”), (A) make and keep available adequate current public
information, as those terms are understood and defined in SEC Rule 144, at all times, (B)
use commercially reasonable efforts to file with the SEC in a timely manner all reports and
other documents required of the Company under the Securities Act and the Exchange Act; and
(C) furnish to the Holder, so long as the Holder owns the Warrant or Warrant Shares,
forthwith upon request (1) a written statement by the Company that it has complied with the
reporting requirements of SEC Rule 144, the Securities Act and the Exchange Act, or that it
qualifies as a registrant whose securities may be resold pursuant to Form S-3, and (2) such
other information as may be reasonably requested in availing the Holder of any rule or
regulation of the SEC that permits the sale of any securities without registration or
pursuant to Form S-3.

(ii) Neither this Warrant nor any certificate or instrument evidencing this Warrant or
the Warrant Shares shall bear (and the Company hereby agrees to remove or not to affix, as
applicable and provided herein) any restrictive or other legend, notice or provision
(including without limitation the legend included on the first page of this Warrant as of
the Issue Date or any similar legend) restricting the sale or transfer of this Warrant or
the Warrant Shares if (A) a transfer of this Warrant or the Warrant Shares is made or
proposed to be made pursuant to SEC Rule 144, (B) a transfer of this Warrant or the Warrant
Shares is made or proposed to be made for no consideration to an Affiliate of the Holder or
(C) such a legend, notice or provision is not required in order to establish compliance with
any provisions of the Securities Act. Within three (3) Trading Days of (X)any written
request by the Holder indicating its intention to make a transfer of this Warrant or all or
a portion of the Warrant Shares pursuant to SEC Rule 144 or (Y) satisfaction of the
registration and prospectus delivery requirements of the Act, the Company shall remove any
such legend, notice or provision and issue a new Warrant and/or Warrant Shares without any
such legend, notice or provision restricting the sale or transfer of this Warrant or the
Warrant Shares, as applicable. Notwithstanding the forgoing or anything to contrary
contained in this Warrant, no certificate or certificates for any shares purchased hereunder
shall bear any restrictive or other legend, notice or provision restricting the sale or
transfer of Warrant Shares if, as of the date of any exercise of this Warrant, the Warrant
Shares may be transferred pursuant to SEC Rule 144 and, if such sale or transfer cannot, as
of such exercise date, be made, the Company shall cause any such legend, notice or provision
to be removed from all or any such certificates within three (3) Trading Days of the first
date on which such a transfer pursuant to SEC Rule 144 can be made. For all purposes of
Section 2(d), the Company shall not be deemed to have delivered to the Holder Warrant Shares
unless and until the Company shall have fully complied with all of the terms and conditions
of this Section 4(d).

Section 5. Miscellaneous.

a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the
Holder to any voting rights, dividends or other rights as a stockholder of the Company prior
to the exercise hereof as set forth in Section 2(d)(i), subject to any express provision of
this Warrant to the contrary.

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants
that upon receipt by the Company of evidence reasonably satisfactory to it of the loss,
theft, destruction or mutilation of this Warrant or any stock certificate relating to the
Warrant Shares, and in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to it (which, in the case of the Warrant, shall not include the
posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or
stock certificate.

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein shall not be
a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

d) Authorized Shares.

The Company covenants that, during the period the Warrant is outstanding, it
will reserve from its authorized and unissued Common Stock a sufficient number of
            shares to provide for the issuance of the Warrant Shares upon the exercise of any
purchase rights under this Warrant. The Company further covenants that its issuance
of this Warrant shall constitute full authority to its officers who are charged with
the duty of executing stock certificates to execute and issue the necessary
certificates for the Warrant Shares upon the exercise of the purchase rights under
this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading
Market upon which the Common Stock may be listed. The Company covenants that all
Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly
authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented to by the Holder, the Company
shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase
the par value of any Warrant Shares above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this
Warrant.

Before taking any action which would result in an adjustment in the number of
Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.

e) Jurisdiction. All questions concerning the construction, validity,
enforcement and interpretation of this Warrant shall be determined in accordance with the
provisions of the Loan Agreement.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon
the exercise of this Warrant, if not registered, and the Holder does not utilize cashless
exercise, will have restrictions upon resale imposed by state and federal securities laws.

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to
exercise any right hereunder on the part of Holder shall operate as a waiver of such right
or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other
provision of this Warrant or the Loan Agreement, if the Company willfully and knowingly
fails to comply with any provision of this Warrant, which results in any material damages to
the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due
pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

h) Notices. Any notice, request or other document required or permitted to be
given or delivered to the Holder by the Company shall be delivered in accordance with the
notice provisions of the Loan Agreement.

i) Limitation of Liability. No provision hereof, in the absence of any
affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to any
liability of the Holder for the purchase price of any Common Stock or as a stockholder of
the Company, whether such liability is asserted by the Company or by creditors of the
Company.

j) Remedies. The Holder, in addition to being entitled to exercise all rights
granted by law, including recovery of damages, will be entitled to specific performance of
its rights under this Warrant. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the provisions of
this Warrant and hereby agrees to waive and not to assert the defense in any action for
specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit of and be binding
upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any
Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of
Warrant Shares.

l) Amendment. This Warrant may be modified or amended or the provisions hereof
waived with the written consent of the Company and the Holder.

m) Severability. Wherever possible, each provision of this Warrant shall be
interpreted in such manner as to be effective and valid under applicable law, but if any
provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Headings. The headings used in this Warrant are for the convenience of
reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

1

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized.

Dated: May 27, 2011

	 
	EPICEPT CORPORATION

	By:___________________________________________
Name: _____________________________________
Title:_______________________________________

NOTICE OF EXERCISE

TO: EPICEPT CORPORATION

(1) The undersigned hereby elects to purchase        Warrant Shares of the Company pursuant
to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of
the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] the cancellation of such number of Warrant Shares as is necessary, in
accordance with the formula set forth in subsection 2(c), to exercise this
Warrant with respect to the maximum number of Warrant Shares purchasable
pursuant to the cashless exercise procedure set forth in subsection 2(c).

(3) Please issue a certificate or certificates representing said Warrant Shares in the name of
the undersigned or in such other name as is specified below:

      

The Warrant Shares shall be delivered by physical delivery of a certificate to:

      

      

      

[SIGNATURE OF HOLDER]

Name of Holder:      

Signature of Authorized Signatory of Holder:      

Name of Authorized Signatory:      

Title of Authorized Signatory:      

Date:       

2

ASSIGNMENT FORM

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

FOR VALUE RECEIVED, [      ] all of or [      ] shares of the foregoing Warrant and all rights
evidenced thereby are hereby assigned to

       whose address is

      .

      

Dated:       ,       

	 	 	 	 	 
	Holder’s Signature:
	 	 	—	 
	Holder’s Address:
	 	 	—	 

      

Signature Guaranteed:       

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign the foregoing
Warrant.

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]